

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 182 152 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
26.05.1999 Bulletin 1999/21

(51) Int Cl. 6: **C12P 1/06, C07G 11/00,**
A61K 35/66, C12N 1/20
// (C12P1/06, C12R1:29,
C12N1:20, C12R1:29)

(21) Application number: **85113751.3**(22) Date of filing: **29.10.1985**(54) **Antitumor antibiotics (LL-E33288 Complex)****Antitumorale Antibiotika (Komplex LL-E-33288)****Antibiotiques antitumoraux (complexe LL-E33288)**

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

(30) Priority: **16.11.1984 US 672031**
17.10.1985 US 787066

(43) Date of publication of application:
28.05.1986 Bulletin 1986/22

(73) Proprietor: **AMERICAN CYANAMID COMPANY**
Wayne, NJ 07470-8426 (US)

(72) Inventors:

- **Lee, May Dean-Ming**
Monsey New York 10952 (US)
- **Greenstein, Michael**
Suffern New York 10901 (US)
- **Labeda, David Paul**
Peoria Illinois 61614 (US)

(74) Representative:
Wächtershäuser, Günter, Prof. Dr.
Patentanwalt,
Tal 29
80331 München (DE)

(56) References cited:

- CHEMICAL ABSTRACTS, vol. 103, no. 9, 2nd September 1985, page 525, abstract no. 69796b, Columbus, Ohio, US; & JP-A-60 24 195 (KYOWA HAKKO KOGYO CO., LTD) 06-02-1985
- CHEMICAL ABSTRACTS, vol. 102, no. 23, 10th June 1985, page 341, abstract no. 200941u, Columbus, Ohio, US; M.S. PUAR et al.: "The biosynthesis of hazimycins: possible origin of isonitrile carbon", & J. ANTIBIOT. 1985, 38(4), 530-2
- CHEMICAL ABSTRACTS, vol. 101, no. 13, 24th September 1984, page 497, abstract no. 1088811, Columbus, Ohio, US; M. ZHAO et al.: "Studies on sagamicin produced by *M. echinospora* mutant strain. II. Selection and fermentation of *M. echinospora* JIM-401", & KANGSHENG SU 1984, 9(2), 90-3
- CHEMICAL ABSTRACTS, vol. 96, 1982, pag 278-279, abstract no. 118046e, Columbus, Ohio, US; Y. IKEDA et al.: "Dolriacollide, a new beta-lactamase inhibitor", & J. ANTIBIOT. 1981, 34(12), 1628-30
- CHEMICAL ABSTRACTS, vol. 94, 1981, pag 396, abstract no. 99356w, Columbus, Ohio, US; H. MAEHR et al.: "Microbial products. IV, X-14847, a new amynoglycoside from *Micromonospora echinospora*", & J. ANTIBIOT. 1980, 33(12), 1431-6
- CHEMICAL ABSTRACTS, vol. 92, 1980, page 502, abstract no. 74356s, Columbus, Ohio, US; & HU-A-17 055 (CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA Rt.) 28-09-79

EP 0 182 152 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent grant. Notice of opposition shall be filed in writing and in a reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] This invention relates to new antibacterial and antitumor agents designated LL-E33288 α_1 -Br, LL-E33288 α_1 -I, LL-E33288 α_2 -Br, LL-E33288 α_2 -I, LL-E33288 α_3 -Br, LL-E33288 α_3 -I, LL-E33288 α_4 -Br, LL-E33288 β_1 -Br, LL-E33288 β_1 -I, LL-E33288 β_2 -Br, LL-E33288 β_2 -I, LL-E33288 γ_1 -Br, LL-E33288 γ_1 -I and LL-E33288 δ_1 -I, to their production by fermentation, to methods for their recovery and concentration from crude solutions and to processes for their purification. The present invention includes within its scope the antibacterial and antitumor agents in dilute form, as crude concentrates, as a complex of various or all components, in pure form as individual components and novel strains of *Micromonospora*.

[0002] The LL-E33288 antibiotics of this invention are closely related compounds. The fourteen antibiotics are recovered from fermentation and are initially obtained as a mixture, hereinafter either the LL-E33288 complex, the the LL-E33288 Iodo-complex or the LL-E33288 Bromo-complex. In general, the iodine containing components of the LL-E33288 antibiotics (e.g., α_1 -I, α_2 -I, α_3 -I, β_1 -I, β_2 -I, γ_1 -I and δ_1 -I) are found only in fermentations using media containing inorganic or organic iodide while the bromine containing components (e.g., α_1 -Br, α_2 -Br, α_3 -Br, α_4 -Br, β_1 -Br, β_2 -Br and γ_1 -Br) are found only in fermentations using media containing inorganic or organic bromide. The ratio of components in the LL-E33288 complex will vary, depending upon the fermentation of both the bromine and the iodine containing antibiotics, LL-E33288 β_1 and LL-E33288 γ_1 are the major components, together accounting for approximately 90% of the complex. LL-E33288 α_1 , LL-E33288 α_2 , LL-E33288 α_3 , LL-E33288 α_4 -Br, LL-E33288 β_2 and LL-E33288 δ_1 -I are minor components, together accounting for approximately 10% of the complex.

[0003] The LL-E33288 antibiotics are active against gram-positive and gram-negative bacteria. Each of the components were also found to be active in a modification of the Biochemical Induction Assay [Elespuru, R. and Yarmolinsky, M., Environmental Mutagenesis, 1, 65-78 1979)], a test which specifically measures the ability of an agent to directly or indirectly initiate DNA damage. In this assay, both LL-E33288 β_1 -Br and LL-E33288 γ_1 -Br were active at concentrations lower than 1×10^{-6} mcg/ml.

BRIEF DESCRIPTION OF THE DRAWINGS**[0004]**

FIG. I is the ultraviolet absorption spectra of LL-E33288 β_1 -Br;
 FIG. II is the infrared absorption spectrum of LL-E33288 β_1 -Br;
 FIG. III is the proton magnetic resonance spectrum of LL-E33288 β_1 -Br;
 FIG. IV is the carbon 13 magnetic resonance spectrum of LL-E33288 β_1 -Br;
 FIG. V is the ultraviolet absorption spectra of LL-E33288 γ_1 -Br;
 FIG. VI is the infrared absorption spectrum of LL-E33288 γ_1 -Br;
 FIG. VII is the proton magnetic resonance spectrum of LL-E33288 γ_1 -Br;
 FIG. VIII is the carbon 13 magnetic resonance spectrum of LL-E33288 γ_1 -Br;
 FIG. IX is the proton magnetic resonance spectrum of LL-E33288 α_2 -I;
 FIG. X is the proton magnetic resonance spectrum of LL-E33288 α_3 -I;
 FIG. XI is the ultraviolet absorption spectra of LL-E33288 β_1 -I;
 FIG. XII is the infrared absorption spectrum of LL-E33288 β_1 -I;
 FIG. XIII is the protein magnetic resonance spectrum of LL-E33288 β_1 -I;
 FIG. XIV is the carbon 13 magnetic resonance spectrum of LL-E33288 β_1 -I;
 FIG. XV is the ultraviolet absorption spectra of LL-E33288 γ_1 -I;
 FIG. XVI is the infrared absorption spectrum of LL-E33288 γ_1 -I;
 FIG. XVII is the proton magnetic resonance spectrum of LL-E33288 γ_1 -I; and
 FIG. XVIII is the carbon 13 magnetic resonance spectrum of LL-E33288 γ_1 -I.

DETAILED DESCRIPTION OF THE INVENTION

[0005] The physico-chemical characteristics of LL-E33288 β_1 -Br and LL-E33288 γ_1 -Br are described below:
LL-E33288 β_1 -Br

- 1) Approximate elemental analysis: C 48.6; H 5.6; N 2.9; S 9.1; and Br 5.5. (It has been determined by electron spectroscopy for chemical analysis (ESCA) that only the following elements are present: C, H, N, O, S and Br);
- 2) Melting point: 146-150°C (dec.);
- 3) Specific rotation: $[\alpha]_D^{26} = -49 \pm 10^\circ$ (0.1% ethanol);
- 4) Ultraviolet absorption spectra: as shown in Figure I (methanol; acidic methanol; basic methanol);
- 5) Infrared absorption spectrum: as shown in Figure II (KBr disc);

EP 0 182 152 B1

- 6) Proton magnetic resonance spectrum: as shown in Figure III (300 MHz, CDCl₃);
 7) Carbon-13 magnetic resonance spectrum: as shown in Figure IV (75.43 MHz, CDCl₃, ppm from TMS), significant peaks as listed below:

5	17.60(q); 22.4(q); 36.9(t); 52.7(q); 57.8(d); 66.9(d); 70.2(d); 76.1(d); 97.4(d); 115.1(s); 130.2(s); 149.5(s);	17.64(q); 22.8(q); 39.2 (t/d); 54.6 (t/d); 61.0 (q/d); 68.4(d); 71.1(d); 81.0(d); 99.7(d); 123.4(d); 130.8(s); 191.7(s);	18.9(q); 23.5(q); 47.8(d); 56.3(q); 61.7(d); 69.1(d); 71.9(d); 83.3(s); 100.8(s); 124.4(d); 144.6(s); 192.4(s);	19.7(q); 34.3(t); 51.7(q); 57.2(q); 62.4(t); 69.7(d); 72.1(s/t); 88.2(s); 102.5(d); 126.5(d); 149.3(s);
---	--	---	--	---

- 20 8) Molecular weight: 1333/1335 respectively for ⁷⁹Br/⁸¹ Br as determined by FAB-MS; and
 9) Molecular formula: C₅₄H₈₄N₃O₂₂S₄Br, exact masses at 1258.3699 (⁷⁹Br) and 1260.3726(⁸¹Br) was determined by high resolution FAB-MS and calculated to be C₅₂H₈₁N₃O₂₁S₃Br (M+H-C₂H₄OS).

LL-E33288 γ_1 -Br

- 25 1) Ultraviolet absorption spectra: as shown in Figure V (methanol; acidic methanol; basic methanol);
 2) Infrared absorption spectrum: as shown in Figure VI (KBr disc);
 3) Proton magnetic resonance spectrum: as shown in Figure VII (300 MHz, CDCl₃);
 4) Carbon 13 magnetic resonance spectrum: as shown in Figure VIII (75.43 MHZ, CDCl₃, ppm from TMS), significant peaks as listed below:

30	14.4 19.7 - 42.1 54.1 59.3 67.2 70.1 71.8 82.9 100.0 115.3 130.4 144.7 155.6	17.6 - 34.0 - 56.3 61.1 68.18 70.8 76.1 88.4 100.2 123.0 131.1 - 192.5	17.9 22.8 37.6 51.6 57.3 61.8 68.23 71.1 - - 101.3 124.9 131.8 149.5 192.9	19.0 - 39.5 52.7 - 61.9 69.7 71.7 81.0 97.8 103.0 126.9 138.0 149.6
----	--	--	--	--

- 35 5) Molecular formula: C₅₃H₈₂N₃O₂₂S₄Br by comparing its UV, IR, ¹H NMR, and ¹³C NMR data to those of LL-E33288 β_1 -Br and LL-E33288 γ_1 -I; and
 6) Molecular weight: 1319/1321 respectively for ⁷⁹Br/⁸¹ Br, calculated from its molecular formula.

[0006] The physico-chemical characteristics of LL-E33288 α_1 -I, LL-E33288 α_2 -I, LL-E33288 α_3 -I, and LL-E33288 β_1 -I and LL-E33288 γ_1 -I are described below:

LL-E33288 α_1 -I

- 55 1) Molecular weight: 1145, determined by FAB-MS.

EP 0 182 152 B1

LL-E33288 α_2 -I

- 5 1) Contains and only contains the following elements by electron spectroscopy for chemical analysis (ESCA): C, H, N, O, S, I;
2) Molecular weight: 1131, determined by FAB-MS; and
3) Proton magnetic resonance spectrum: as shown in Figure IX (300 MHz, CDCl₃).

LL-E33288 α_3 -I

- 10 1) Molecular weight: 1066, determined by FAB-MS; and
2) Proton magnetic resonance spectrum: as shown in Figure X (300 MHz, CDCl₃).

LL-E33288 β_1 -I

- 15 1) Ultraviolet absorption spectra: as shown in Figure XI (methanol; acidic methanol; basic methanol);
2) Infrared absorption spectrum: as shown in Figure XII (KBr disc);
3) Proton magnetic resonance spectrum: as shown in Figure XIII (300 MHz, CDCl₃);
4) Carbon 13 magnetic resonance spectrum: as shown in Figure XIV (75.43 MHz, CDCl₃, ppm from TMS), significant peaks as listed below:

20	-	17.5	17.6	18.9
	-	22.4	22.8	23.4
25	25.4	34.3	36.9	39.2
	-	47.9	51.6	52.8
	54.8	56.3	57.2	57.9
	60.9		61.6	62.2
	67.0	68.4	68.4	69.1
30	69.6	70.4	71.1	71.8
	72.2	76.2	-	80.8
	83.3	88.1	93.6	97.4
	99.6	99.6	-	102.6
35	112.4	123.4	124.4	126.4
	-	-	133.4	-
	-	192.3	192.6	

- 40 5) Molecular formula: C₅₄H₈₄N₃O₂₂S₄I by comparing its UV, IR, ¹H NMR and ¹³C NMR data to those of LL-E33288 β_1 -Br and LL-E33288 γ_1 -I; and
6) Molecular weight: 1381, calculated from molecular formula.

LL-E33288 γ_1 -I

- 45 1) Contains and only contains the following elements by electron spectroscopy for chemical analysis (ESCA): C, H, N, O, S, I;
2) Approximate elemental analysis: C 48.8; H 5.4; N 2.8; S 9.0; I 9.2;
3) Molecular weight: 1367, determined by FAB-MS;
4) Molecular formula: C₅₃H₈₂N₃O₂₂S₄I, exact mass for M+H was determined by high resolution FAB-MS to be 1368. 3397 for C₅₃H₈₃N₃O₂₂S₄I;
5) Ultraviolet absorption spectra: as shown in Figure XV (methanol; acidic methanol; basic methanol);
50 6) Infrared absorption spectrum: as shown in Figure XVI (KBr disc);
7) Proton magnetic resonance spectrum: as shown in Figure XVII (300 MHz, CDCl₃); and
8) Carbon 13 magnetic resonance spectrum: as shown in Figure XVIII (75.43 MHz, CDCl₃, ppm for TMS) significant peaks as listed below:

14.5(q)	17.6(q)	17.6(q)	18.9(q)
---------	---------	---------	---------

(continued)

-	-	22.8(q)	-
25.4(q)	34.1(t)	37.0(t)	39.1(t)
42.3(t/s)	-	51.5(d)	52.8(q)
54.8(t)	56.3(q)	57.2(q)	-
60.4(d)	60.9(q)	61.3(t)	61.7(q)
67.0(d)	68.4(d)	68.5(d)	69.2(d)
69.7(d)	70.5(d)	71.1(d)	71.8(d)
72.1(s)	75.7(d)	75.8(d)	80.9(d)
82.8(s) 99.6(d)	88.1(s) 99.7(d)	93.5(s) 100.8(s)	97.3(d) 102.6(d)
-	123.4(d)	124.4(d)	126.2(d)
130.2(s)	131.0(s)	133.4(s)	139.1(s)
143.0(s)	145.1	150.6(s)	151.5(s)
154.5	192.0(s)	192.5(s)	

[0007] The LL-E33288 components are most conveniently separated and identified by high-performance liquid chromatography (HPLC) and by thin-layer chromatography (TLC). It is difficult, although not impossible, to separate the corresponding iodinated and brominated components by HPLC; however, they cannot be distinguished by TLC.

[0008] The preferred analytical separation of the LL-E33288-Br components by HPLC uses the following conditions:

Column:	"Separalyte C ₁₈ 5 m," 4.6 mm x 25 cm (Analytichem International);
Solvent:	Acetonitrile: 0.2 <u>M</u> aqueous ammonium acetate (60:40);
Flow rate:	1.5 ml/minute
Detector:	Dual wavelength UV at 254 nm and 280 nm;
Sensitivity:	0-0.02 A.U.F.S.

[0009] Table IA gives the approximate retention times and volumes of LL-E33288 β_1 -Br, LL-E33288 β_2 -Br, and LL-E33288 γ_1 -Br under these conditions.

TABLE IA

LL-E33288 Components	Retention Time (minutes)	Retention Volume(ml)
β_1 -Br	5.7	8.6
β_2 -Br	7.1	10.7
γ_1 -Br	4.3	6.5

[0010] The preferred analytical HPLC separation of the iodine containing LL-E33288 components uses the following conditions:

Column:	NOVA-PAK C ₁₆ Radial-PAK cartridge with RCM-100 Radial Compression Module (Millipore, Waters Chromatography Division);
Solvent:	Acetonitrile: 0.2 <u>M</u> aqueous ammonium acetate (50:50);
Flow Rate:	1.2 ml/minute;
Detector:	Dual wavelength UV at 254 nm and 280 nm;

EP 0 182 152 B1

(continued)

Sensitivity:	0.02 A.U.F.S.
--------------	---------------

[0011] Table IB gives the approximate retention times and volumes of LL-E33288 α_1 -I, LL-E33288 α_2 -I, LL-E33288 α_3 -I, LL-E33288 β_1 -I, LL-E33288 β_2 -I, LL-E33288 γ_1 -I and LL-E33288 δ_1 -I under these conditions.

TABLE IB

LL-E33288 Components	Retention Time (minutes)	Retention Volume(ml)
α_1 -I	11.9	14.3
α_2 -I	9.1	10.9
α_3 -I	1.5	1.8
β_1 -I	4.4	5.3
β_2 -I	5.0	6.0
γ_1 -I	3.6	4.3
δ_1 -I	2.6	3.1

[0012] The LL-E33288 components are separated and identified by the following TLC system:

Adsorbant:	Silica gel 60 F ₂₅₄ pre-coated aluminum sheets, 0.2mm layer thickness, EM Reagents;	
Detection:	Visualized by quenching effect under short wavelength UV lamp (254 nm), and bioautography using <u>Bacillus subtilis</u> or the modified biochemical induction assay;	
Solvent Systems:	I,	ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate;
	II,	3% isopropyl alcohol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate;
	III,	ethyl acetate:methanol (95.5).

[0013] Table II gives the approximate R_f values of LL-E33288 components in these three systems:

TABLE II

LL-E33288 Components	R _f Value		
	Solvent System I	Solvent System II	Solvent System III
α_1 -Br, α_1 -I	0.67	0.80	0.79
α_2 -Br, α_2 -I	0.61	0.75	0.73
α_3 -Br, α_3 -I	0.55	0.69	0.61
α_4 -Br	0.49	0.64	0.54
β_2 -Br, β_2 -I	0.32	0.41	0.45
β_1 -Br, β_1 -I	0.24	0.35	0.36
γ_1 -Br, γ_1 -I	0.18	0.28	0.27

EP 0 182 152 B1

TABLE II (continued)

LL-E33288 Components	R _f Value		
	Solvent System I	Solvent System II	Solvent System III
δ ₁ -I	0.11	0.19	

[0014] The new antibacterial and antitumor agents designated LL-E33288α₁-Br, LL-E33288α₂-Br, LL-E33288α₃-Br, LL-E33288α₄-Br, LL-E33288β₁-Br, LL-E33288β₂-Br, LL-E33288γ₁-Br, LL-E33288α₁-I, LL-E33288α₂-I, LL-E33288α₃-I, LL-E33288β₁-I, LL-E33288β₂-I, LL-E33288γ₁-I and LL-E33288δ₁-I are formed during the cultivation under controlled conditions of a new strain of Micromonospora echinospora ssp. calicensis. This microorganism is maintained in the culture collection of the Medical Research Division, American Cyanamid Company, Pearl River, New York as culture number LL-E33288. A viable culture of this new microorganism has been deposited with the Culture Collection Laboratory, Northern Regional Research Center, U. S. Department of Agriculture, Peoria, Illinois on August 9, 1984, and has been added to its permanent collection. It has been assigned by such depository the strain designation NRRL 15839. Access to such culture, under strain designation NRRL 15839, during pendency of the instant application shall be available to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122, and all restrictions on availability to the public of such culture will be irrevocably removed upon grant of a patent on the instant application.

[0015] Culture LL-E33288 was isolated from a caliche clay soil sample collected in Texas.

[0016] The generic assignment of the strain NRRL 15839 to the genus Micromonospora was confirmed morphologically and chemically. The strain produces monospores either singly or in masses on the vegetative hyphae. No aerial hyphae were observed. Electron microscopic examination showed that the spores were warty. Whole cell analysis showed that the strain contained the meso isomer of diaminopimelic acid (DAP). The 3-OH derivative of DAP was present in large (major) amounts. Additionally the strain showed the presence of xylose plus traces of arabinose in its whole cell sugar hydrolysates (whole cell sugar pattern of Type D).

[0017] From macromorphological and physiological studies it was concluded that NRRL 15839 can be considered subspecies of M. echinospora (it is closest to M. echinospora ssp. pallida). Data on the morphology of NRRL 15839 are given in Tables A and B. Physiological data are given in Tables C and D.

Table A

Macromorphology Of NRRL 15839 (Colors Are NBS-ISCC)			
ISP Agar Medium	Spores	Vegetative Mycelium	Soluble Pigments
Yeast-Malt (ISP 2)	-	Dark orange-yellow (72)	-
Oatmeal (ISP 3)	-	Colorless → pale orange-yellow (73)	-
Inorganic Salts-Starch (ISP 4)	Slight border of black spores	Dark orange-yellow (72) to lt. yellow-brown (76)	Lt. brownish
Glycerol-Asparagine (ISP 5)	-	Pale orange-yellow (73) → colorless	-

Table B

Macromorphology of NRRL-15839 on Various Agar Media Used for Actinomycete Growth (28°C, 2 weeks)	
Agar Medium	NRRL-15839
Pabulum	Beige veg. Sl. black spores No sol. pig.
Yeast Czapeks	Beige veg. No spores No sol. pig.
Czapek's	Beige veg. Sl. black spores No sol. pig.

EP 0 182 152 B1

Table B (continued)

Macromorphology of NRRL-15839 on Various Agar Media Used for Actinomycete Growth (28°C, 2 weeks)

Agar Medium	NRRL-15839
Yeast Dextrose	Tan veg. Moderate black sp. Sl. dark pig.
Nutrient	Colorless to can veg. Sl. black spores No sol. pig.
Nutrient-Glycerol	Colorless to light beige veg. No black spores No sol. pig.
Bennett's Dextrin	Colorless to beige veg. Sl. black spores Sl. rosy-brown pig.
Glucose-Asparagine	Colorless to lt. orange-beige veg. No spores No sol. pig.

veg. = vegetative hyphae; pig. = pigment.

Table C

Carbohydrate Utilization of NRRL-15839	
Arabinose	+
Cellulose	-
Fructose	+
Glucose	+
Inositol	-
Mannitol	-
Raffinose	±
Rhamnose	+
Sucrose	+
Xylose	+

Table D

Physiological Reactions of NRRL-15839	
Hydrolysis of	
Casein	+
Xanthine	-
Hypoxanthine	-
Tyrosine	+
Adenine	-
Gelatin	+
Potato Starch	+

EP 0 182 152 B1

Table D (continued)

Physiological Reactions of NRRL-15839		
Hydrolysis of		
5	Esculin	+
Production of		
10	Nitrate Reductase Phospatase Urease	+ W -
Growth on		
15	Salicin 5% NaCl Lysozyme Broth	- - -
Decarboxylation of		
20	Acetate Benzoate Citrate Lactate Malate Mucate Oxalate Propionate Pyruvate Succinate Tartrate	++ - - - - - - + + - -
25		
30		
35		
Acid from		
40	Adonitol Arabinose Celllobiose Dextrin Dulcitol Erythritol Fructose Galactose Glucose Glycerol Inositol Lactose Maltose Mannitol Mannose α -methyl D Glucoside Melibiose Raffinose Rhamnose	- + + + - - + V + - - + - + - - +
45		
50		
55		

EP 0 182 152 B1

Table D (continued)

Physiological Reactions of NRRL-15839	
Acid from	
5	Salicin +
	Sorbitol -
	Sucrose +
	Trehalose +
10	Xylose +
	β -Methyl D-xyloside -
Growth at	
15	10° -
	42° +
	45° +

+ = positive; - = negative; V = variable; W = weak.

20 Derivation of Mutant LL-E33288-R66, NRRL-15975

[0018] In an effort to improve fermentation yields, the orginal culture LL-E33288 (NRRL-15839) was plated and 50 single colonies were isolated. These were designated NS1 to NS50 (NS = natural selection).

[0019] Fermentation of these isolates showed that those with moderate sporulation were generally better producers of LL-E33288 complex. Selected as representative of this group was isolate NS6.

[0020] Using isolate NS6 as the starting culture, spore suspensions were prepared and exposed to various mutagens. Single colonies were isolated from a nitroso guanidine treatment, but none proved to be significantly improved producers of the LL-E33288 complex. From a subsequent series of exposures to ultraviolet irradiation, single colonies were obtained from which isolate UV 610 was selected as a high yielding mutant. Isolate UV 610 was then streaked and sub-isolates 1 to 7 were obtained. Sub-isolate UV 610(3) was selected for further work.

[0021] Because of the highly potent antibacterial and antineoplastic nature of the LL-E33288 complex it is possible that once a limited concentration of the antibiotic is biosynthesized in the fermentation it may become toxic/inhibitory to the producing culture. Thus, an effort was made to obtain isolates which are resistant to the LL-E33288 antibiotic complex.


[0022] Vegetative growth from isolate UV 610(3) was prepared as employed for fermentation and used to inoculate a flask of medium consisting of peptone, dextrose, molasses and water. The medium was supplemented with LL-E33288 β_1 -Br at a concentration of 8 μ g/m. A number of platings were done from this flask and a resistant population was obtained on the seventh day. A total of 97 colonies (R1 to R97) were isolated. Isolate R66 was selected as a potentially improved producer of LL-E33288 β_1 -Br.

[0023] The history is represented schematically below.

45

50

55



[0024] The mutant R66 is maintained in the culture collection of the Medical Research Division, American Cyanamid Company, Pearl river, New York as culture number LL-E33288 R66. A viable culture of this new microorganism has been deposited with the Culture Collection Laboratory, Northern Regional Research center, U. S. Department of Agriculture, Peoria, Illinois on June 6, 1985, and has been added to its permanent collection. It has been assigned by such depository the strain designation NRRL 15975. Access to such culture, under strain designation NRRL 15975, during pendency of the instant application shall be available to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under C.F.R. §1.14 and 35 U.S.C. §122, and all restrictions on availability to the public of such culture will be irrevocably removed upon grant of a patent on the instant application.

[0025] Morphologically, NRRL-15975 forms fewer spores than NRRL-15839. A comparison of NRRL-15975 with NRRL-15839 is given in Table DD.

[0026] Chemically, both NRRL-15839 and NRRL-15975 show the same whole cell sugar patterns (Type D: xylose and traces of arabinose). The whole cell diaminopimelic acid analysis reveals that 15975 does not form the meso isomer but only the 3-hydroxy derivative (NRRL-15839 contains both compounds). This does not change the chemo-taxonomic assignment.

[0027] Physiological tests show that NRRL-15839 and NRRL-15975 differ in only two physiological reaction (See Table D). NRRL-15975 is negative for nitrate reductase and positive for utilization of lactate. NRRL-15839 was weakly positive for both, but is now negative after having been maintained on slants for a few months. Thus these characters should be considered variable for this taxon.

TABLE DD

Morphological Comparison of NRRL 15839 and NRRL 15975			
	Agar Medium	NRRL 15839	NRRL 15975
5	Bennett's-Dextrin	V ¹	Beige-can
		Sp	Black, copious
		SS	None
10	Czapek's	V Sp	Orange-tan Blac , traces
		SS	None
15	Yeast Extract-Czapek's	V Sp	Orange tan, flat Black, traces
		SS	None
			Orange tan, convoluted None
20	Potato-Dextrose	V	Very poor growth
		Sp	None
		SS	None
25	Nutrient glycerol	V	Tan
		Sp SS	Black, sparse None
			Black, sparse Slight brownish
30	Nutrient	V	Tan
		Sp	Black, fair
		SS	None

1 = V = vegetative hyphae; Sp = spores; SS = soluble pigment.

- 35 [0028] It is to be understood that for the production of these new antibacterial and antitumor agents the present invention is not limited to this particular organisms or to organisms fully answering the above growth microscopic characteristics which were given for illustrative purposes only. In fact, it is desired and intended to include the use of mutants produced from these organisms by various means such as exposure to X-radiation, ultraviolet radiation, N-methyl-N'-nitro-N-nitrosoguanidine, actinophages and the like.
- 40 [0029] The *in vitro* antibacterial activity of LL-E33288 components was determined against a spectrum of gram-positive and gram-negative bacteria by a standard agar dilution method. Mueller-Hinton again containing two-fold decreasing concentrations of the antibiotics were poured into petri plates. the agar surfaces were inoculated with 1 to 5 $\times 10^4$ colong forming units of bacteria by means of the steers replicating device. The lowest concentration of LL-E33288 component that inhibited growth of a bacterial strain after about 18 hours of incubation at approximately 35°C was recorded as the minimal inhibitory concentration (MIC) for that strain. The results are summarized in Table III.

TABLE III
In vitro Antibacterial Activity of LL-E33288 Components

Organism	Minimal Inhibitory Concentration, mcg/ml		
	B1-Br	B1-I	Y1-Br
<u>Escherichia coli</u>			
CMC 84-11	0.25	0.50	0.50
No. 3111-(MP)	0.12	0.25	0.25
" "			
ATCC 25922	0.12	0.25	0.25
<u>Klebsiella pneumoniae</u>			
CMC 84-5	0.25	0.50	0.50
" "			
AD (MP)	0.12	0.50	0.50
<u>Enterobacter cloacae</u>			
CMC 84-4	0.5	0.50	0.50
" <u>aerogenes</u>			
10 83-44	0.25	0.25	0.50
<u>Serratia marcescens</u>			
CMC 83-27	0.12	0.25	0.50
" "			
F35 (MP)	0.12	0.50	0.25
<u>Morganella morganii</u>			
10 83-18	0.5	1	0.50
<u>Providencia stuartii</u>			
CMC 83-82	0.25	0.50	1
<u>Citrobacter diversus</u>			
K 82-84	0.12	0.50	0.50
" <u>freundii</u>			
10 83-13	0.12	0.25	0.25
<u>Acinetobacter sp.</u>			
CMC 83-89	0.06	0.25	0.12
" sp.	0.12	0.25	0.06

5
10
15
20
25
30
35
40
45
50
55

TABLE III (continued)

Organism	Minimal Inhibitory Concentration, mcg/ml			
	B1-Br	B1-I	Y1-Br	Y1-I
<u>Pseudomonas aeruginosa</u>	12-4-4 (MP)	0.5	0.50	1
"	ATCC 27853	0.25	0.25	0.50
<u>Staphylococcus aureus</u>	Smith	<0.0025	<0.000031	<0.000031
"	SSC 82-31	<0.00025	<0.000031	<0.000031
"	ATCC 25923	<0.00025	<0.000031	<0.000031
"	SSC 82-20	<0.00025	<0.000031	<0.000031
"	SSC 82-26	<0.00025	<0.000031	<0.000031
"	SSC 82-24	<0.00025	<0.000031	<0.000031
"	SSC 82-57	<0.00025	<0.000031	<0.000031
<u>Staphylococcus epidermidis</u>	CMC-83-133	<0.00025	<0.000031	<0.000031
"	ATCC 12228	<0.00025	<0.000031	<0.000031
<u>Enterococcus</u> sp.	CMC 83-53	0.0038	0.031	0.062
<u>Streptococcus faecalis</u>	ATCC 29212	<0.00025	0.00012	<0.000031
<u>Micrococcus luteus</u>	PCI 1001	<0.00025	<0.000031	<0.000031
<u>Bacillus subtilis</u>	ATCC	<0.00025	<0.000031	<0.000031

[0030] Certain in vivo testing systems and protocols have been developed by the National Cancer Institute for testing compounds to determine their suitability as anti-neoplastic agents. These have been reported in "Cancer Chemotherapy Reports", Part III, Vol. 3, No. 2 (1972), G. Ran, et al. These protocols have established standardized screening tests which are generally followed in the field of testing for antitumor agents. Of these systems, lymphocytic leukemia P388, melanotic melanoma B16, L1210 leukemia and colon 26 adenocarcinoma are particularly significant to the present invention. These neoplasms are utilized for testing as transplantable tumors in mice. Generally, significant anti-tumor activity, shown in these protocols by a percentage increase of mean survival times of the treated animals (T) over the control animals (C), is indicative of similar results in human leukemias and solid tumors.

10 Lymphocytic Leukemia P388 Test

[0031] The animals used were BDF₁ mice, all of one sex, weighing a minimum of 17 g and all within a 3 g weight range. There were 5 or 6 mice per test group. The tumor transplant was by intraperitoneal injection of 0.5 ml of dilute ascitic fluid containing 10⁶ cells of lymphocytic leukemia P388. LL-E33288 antibiotics were tested in the P388 system both as the individual β_1 -Br and γ_1 -Br components and as a complex of all components (Bromo-complex). These compounds were administered intraperitoneally at a volume of 0.5 ml in 0.2% Klucel in normal saline on days 1, 5 and 9 (relative to tumor inoculation) at the indicated doses. The mice were weighed and the survivors recorded on a regular basis for 30 days. The median survival time and the ratio of survival time for treated (T)/control (C) animals were calculated. The positive control compound was Cisplatin given as an intraperitoneal injection in 0.5 ml of 0.2% Klucel on days 1, 5 and 9 at the indicated doses. The results appear in Table IV.

[0032] If T/C X 100 (%) is 125 or over, the tested compound is considered to have significant anti-tumor activity.

TABLE IV

Lymphocytic Leukemia P388 Test				
	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
25	LL-E33288 (Bromo-complex)	3.2	16.5	156
		1.6	17.5	165
		0.8	18.5	175
		0.4	19	179
		0.2	16.5	156
		Control	10.6	-
30	Positive Control	1.0	21.5	203
		0.25	15	142
		0.06	14.5	137
		LL-E-33288 β_1 -Br	13	105
		0.2	18	145
		0.1	19	153
35		0.05	17.5	141
		0.025	18	145
		0.012	14	113
		Control	12.4	-
		Positive Control	25.5	206
		0.4	19	153
40	LL-E33288 γ_1 -Br	0.06	15	121
		0.2	14	113
		0.1	21	169
		0.05	19.5	157
		0.025	18	145
		0.012	14.5	117

EP 0 182 152 B1

TABLE IV (continued)

Lymphocytic Leukemia P388 Test			
Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
Control	-	12.4	-
Positive Control	1.0	25.5	206
	0.4	19	153
	0.06	15	121

Melanotic Melanoma B16

[0033] The animals used were BDF₁ mice, all of the same sex, weighing a minimum of 17 g and all within a 3 g weight range. There are normally 6 animals per test group. A 1 g portion of melanotic melanoma β_{16} tumor was homogenized in 10 ml of cold balanced salt solution and a 0.5 ml aliquot of the homogenate was implanted intraperitoneally into each of the test mice. LL-E33288 antibiotics were tested in the β_{16} system both as the individual β_1 -Br and γ_1 -Br components and as a complex of all components (Bromo-complex). The test compounds were administered intraperitoneally on days 1 through 9 (relative to tumor inoculation) at various doses. The mice were weighed and survivors recorded on a regular basis for 60 days. The median survival time and the ratio of survival time for treated (T)/control (C) animals were calculated. The positive control compounds were Cisplatin or Adriamycin. The results of this test appear in Table V. If T/C X 100 (%) is 125 or over, the tested compound is considered to have significant anti-tumor activity.

TABLE V

Melanotic Melanoma B ₁₆ Test			
Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
LL-E33288 (Bromo-complex)	0.8	30	188
	0.4	29.5	184
	0.2	27	169
	0.1	24	150
Control	-	16	-
Cisplatin	0.4	25	156
	0.2	25	156
	0.1	23	144
	0.05	21.5	134
LL-E33288 β_1 -Br	0.05	32	168
	0.025	33.5	176
	0.0125	32	168
Control	-	19	-
Adriamycin	0.8	> 60	> 316
	0.4	> 60	> 316
LL-E33288 γ_1 -Br	0.05	33.5	176
	0.025	30	159
	0.0125	37	195

TABLE V (continued)

Melanotic Melanoma B ₁₆ Test				
	Compound	Dose (mg/kg)	Median Survival (Days)	
5	Control	-	19	
10	Adriamycin	0.8 0.4	> 60 > 60	> 316 > 316

Lymphocytic Leukemia L1210 Test

[0034] The animals used were BDF₁ mice, all of one sex, weighing a minimum of 17 g and all within a 3 g weight range. There were 6 mice in each test group and 18 in control groups. The tumor transplant was by intraperitoneal injection of 0.5 ml of lymphocytic leukemia L1210 at a concentration of 10⁵ cells per mouse. LL-E33288 antibiotics were tested in the L1210 system both as the individual β_1 -Br component and as a complex of all components (Bromo-complex). The test compounds were administered on days 1, 5 and 9 or days 1 through 9 (relative to tumor inoculation) at various doses. The mice were weighed and survivors recorded on a regular basis for 30 days. The median survival time and the ratio of survival time for treated (T)/control (C) animals were calculated. The positive control compound was 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone dihydrochloride or Cisplatin given intraperitoneally at the indicated dose. The results appear in Table VI. If T/C X 100 (%) is 125 or over, the tested compound is considered to have significant anti-tumor activity.

TABLE VI

Lymphocytic Leukemia L1210 Test			
	Compound	Dose (mg/kg)	Median Survival (Days)
30	LL-E33288 (Bromo-complex)	1.5	29
		0.8	28.5
		0.4	22.5
		0.2	22.5
35	Control	-	16.7
		1.6	30
		0.8	30
		0.4	30
40	LL-E33288 β_1 -Br	0.2	11.3
		0.1	11.4
		0.05	11
		0.025	11.3
45	Control	-	8.3
		5	7.5
		2.5	12
		1.25	11
50	Cisplatin	-	-
		5	90
		2.5	145
		1.25	133

Colon 26 Adenocarcinoma Test

[0035] The animals used were CD₂F₁ female mice weighing a minimum of 17 g and all within a 3 g weight range. There were 5 or 6 mice per test group with three groups of 5 or 6 animals used as untreated controls for each test. The tumor implant was by intraperitoneal (or subcutaneous) injection of 0.5 ml of a 2% Colon 26 tumor brei in Eagle's

EP 0 182 152 B1

MEM medium containing antibiotics. LL-E33288 antibiotics were tested in the Colon 26 system as a complex (Bromo-complex) of all components. The test compounds were administered intraperitoneally on days 1, 5 and 9 (relative to tumor implant doses). The mice were weighed and deaths recorded on a regular basis for 30 days. The median survival times for treated (T)/control (C) animals were calculated. The positive control compound was Cisplatin. The results appear in Table VII. If T/C X 100 (%) is 130 or over, the tested compound is considered to have significant anti-tumor activity.

TABLE VII

Colon 26 Adenocarcinoma Test			
Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
LL-E33288 (Bromo-complex)	1.5	39.5	212
	0.8	32.5	175
	0.4	34	183
	0.2	25.5	137
Control	-	18.6	-
Positive	1	29	156
Control	0.5	38.5	207
	0.25	37.5	202

M5076 Sarcoma

[0036] The M5076 reticular cell Sarcoma is propagated as subcutaneous implants in C57B2/6 female mice. In the assays for antitumor activity, BDF₁ mice of either sex were inoculated intraperitoneally with 0.5 ml of a 10% tumor br. i. LL-E33288 antibiotics were tested in the M5076 system as a complex (Bromo-complex) of all components. Test compounds were administered intraperitoneally on days 1, 5, 9, 13 and 17 relative to tumor inoculation on day zero. The median survival time in days was determined for each drug dose used on day 60 and the ratio of survival time for treated (T)/control (C) animals were calculated. The results of this test appear in Table VIII compared to the results obtained with Cisplatin. If T/C X 100 (%) is 125 or over, the tested compound is considered to have significant anti-tumor activity.

TABLE VIII

M5076 Sarcoma			
Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
LL-E33288 (Bromo-complex)	1.5	50	175
	0.8	50	175
	0.4	39.5	139
Control	-	28.5	-
Cisplatin	1	30	105
	0.5	44.5	156
	0.25	45	158

[0037] In the same manner, the following iodo-components were tested for antineoplastic activity.

TABLE IX

Lymphocytic Leukemia P388 Test			
Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
LL-E33288 γ_1 -I (Test 1)	.005	>25.5	>196
	.0025	22	169
	.00125	18.5	142

EP 0 182 152 B1

TABLE IX (continued)

Lymphocytic Leukemia P388 Test				
	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
5		.0006 .0003 .00015	18 15.5 15	138 119 115
10	Control	-	13	-
	Positive Control Novantrone®*	1.6	22.5	173
15	LL-E33288 γ_1 -I (Test 2)	.01 .005 .0025 .00125 .0006 .0003 .00015	11 18 22.5 18.5 16 14 14	100 164 205 168 145 127 127
20	Control	-	11	-
25	Positive Control Novantrone®	1.6 0.8	19 16	173 145

*1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl] amino]anthraquinone-2HCl

TABLE X

Melanotic Melanoma B ₁₆ Test				
	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
35	LL-E33288 γ_1 -I	.0025 .00125 .0006 .0003 .00015 .00007	26.5 27 42.5 35.5 33.5 30.5	156 159 250 209 197 179
40	Control	-		-
45	Adriamycin	0.8 0.4 0.2	48 40 34.5	282 235 203

TABLE XI

Lymphocytic Leukemia L1210 Test				
	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
55	LL-E33288 γ_1 -I	.01 .005	8 14	89 156

EP 0 182 152 B1

TABLE XI (continued)

Lymphocytic Leukemia L1210 Test				
	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
5		.0025 .0012 .0006	11 10.5 10	122 117 111
10	Control	-	9	-
15	Positive Control Novantrone®	3.2 1.6 0.8 0.4	15 11.5 12 11	167 128 133 122

TABLE XII

Colon 26 Adenocarcinoma Test				
	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 (%)
20	LL-E33288 Y ₁ -I	.01 .005 .0025 .00125 .0006 .0003 .00015 .00007	11 25.5 27 22.5 23.5 20 17.5 17	59 138 146 122 127 108 95 92
25	Control	-	18.5	-
30	Positive Control Cisplatin	2 1 0.5	15.5 27.5 23.5	84 149 127
35				
40				

General Fermentation Conditions

[0038] Cultivation of Micromonospora echinospora NRRL 15839 or NRRL 15975 may be carried out in a wide variety of liquid culture media. Media which are useful for the production of these novel antibacterial and antitumor agents include an assimilable source of carbon, such as starch, sugar, molasses, glycerol, etc.; an assimilable source of nitrogen such as protein, protein hydrolysate, polypeptides, amino acids, corn steep liquor, etc.; and inorganic anions and cations, such as potassium, sodium, ammonium, calcium, sulfate, carbonate, phosphate, chloride, etc. and sources of either bromine (sodium bromide) or iodine (potassium iodide). Trace elements such as boron, molybdenum, copper, etc., are supplied as impurities of other constituents of the media. Aeration in tanks and bottles is supplied by forcing sterile air through or onto the surface of the fermenting medium. Further agitation in tanks is provided by a mechanical impeller. An antifoam agent such as silicone may be added as needed.

General Procedure for the Isolation and Separation of the Antibiotics - LL-E33288

[0039] The LL-E33288 antibiotics are recovered from the fermentation broth by extracting the whole mash with an organic solvent such as ethyl acetate or dichloromethane. The antibiotic complex, contained in the organic extract, is

further purified by selective precipitation from lower hydrocarbons. The crude LL-E-33288 antibiotic complex thus obtained is further purified and separated into the individual components by a series of column chromatographies using silica gel, Sephadex® LH-20 (Pharmacia Fine Chemicals) and C₁₈ bonded silica.

[0040] The invention will be described in greater detail in conjunction with the following non-limiting specific examples.

5

Example 1

10

Inoculum Preparation

15

[0041] A typical medium used to grow the primary inoculum was prepared according to the following formula:

20

Beef extract	about 0.3%
Tryptone	about 0.5%
Dextrose	about 0.5%
Dextrin	about 2.4%
Calcium carbonate	about 0.4%
Yeast extract	about 0.5%
Water qs to	100%

25

[0042] This medium was adjusted to pH 7.0 and then sterilized. A 100 ml portion of this sterile medium, in a flask, was inoculated with frozen mycelia of the culture NRRL 15839. The inoculated medium was placed on a rotary shaker and agitated vigorously for 48 hours at 32°C. This incubated medium was then used to inoculate 10 liters of the above sterile medium in a 14 liter fermentor. This medium was incubated, with agitation, at 32°C for 48 hours, providing secondary inoculum. This secondary inoculum was then used to inoculate 300 liters of the above sterile medium in a tank and incubated for 48 hours at 30°C while agitated by an impeller driven at 180-200 rpm, providing the tertiary or seed inoculum.

30

Example 2

Tank Fermentation

35

[0043] A fermentation medium was prepared according to the following formulation:

40

Dextrose	about 0.5%
Sucrose	about 1.5%
Peptone, bacteriological grade	about 0.2%
Dibasic potassium phosphate	about 0.01%
Molasses	about 0.5%
Calcium carbonate	about 0.5%
Source of bromine or iodine	trace amounts
Water qs to	100%

45

[0044] A 2800 liter portion of the above medium was sterilized and then inoculated with 300 liters of tertiary (seed) inoculum prepared as described in Example 1. Aeration was supplied at the rate of 0.53 liters of sterile air per liter of mash per minute and agitation was supplied by an impeller driven at 110 rpm. The temperature was maintained at about 28°C and the fermentation was terminated after about 97 hours, at which time the mash was harvested.

50

[0045] The fermentation was monitored for production of the LL-E33288 antibiotics by antibacterial activity, biochemical induction assay, TLC and HPLC analyses.

55

[0046] The whole harvest mash was adjusted to pH 6 and then extracted with 1/2 mash volume ethyl acetate. The ethyl acetate extract was concentrated to a syrup which was washed twice with hexane and filtered through diatomaceous earth. The diatomaceous earth cake was thoroughly mixed with ethyl acetate and filtered. The filtrate was concentrated to 3 liters, dried over excess anhydrous sodium sulfate and then precipitated by the addition of hexane giving about 26.7 g of crude LL-E33288 complex.

Example 3Separation of LL-E33288 α_1 -Br, α_2 -Br, α_3 -Br and α_4 -Br from LL-E33288 β_1 -Br, β_2 -Br and γ_1 -Br

- 5 [0047] The approximately 26.7 g of crude LL-E33288 complex (Bromo-complex) from Example 2 was divided evenly into three portions and chromatographed on three separate 2.4 x 110 cm silica gel columns (Silica Woelm®, 32-63 m, Woelm Pharma) packed and equilibrated with ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate. The columns were first eluted with the same solvent at a flow rate of 3 ml/minute for 18 hours, collecting 18 ml fractions. The eluent was changed to ethyl acetate:methanol (95:5) and elution continued for 8 hours. Finally the columns were eluted with ethyl acetate:methanol (90:10) for 10 hours. The fractions were assayed by the modified biochemical induction assay (BIA). The positive fractions were analysed by TLC using silica gel 60 precoated sheets and developed with the solvent system 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate and detected by bioautography using the modified BIA.
- 10 [0048] Fractions containing LL-E33288 α_1 -Br, α_2 -Br, α_3 -Br and α_4 -Br (LL-E33288 α -Br complex) from the three columns were pooled, concentrated to dryness and the residue was dissolved in ethyl acetate and washed with a small amount of water. The ethyl acetate solution was dried over anhydrous sodium sulfate and precipitated as before to yield about 4.2 g of crude LL-E33288 α -Br complex.
- 15 [0049] Fractions containing LL-E33288 β_2 -Br, β_1 -Br and γ_1 -Br (LL-E33288 β -Br complex containing γ -Br from the three columns were pooled and worked up as above to yield about 2.0 g of crude LL-E33288 β -Br complex containing γ -Br.
- 20

Example 4Isolation of LL-E33288 β_1 -Br and LL-E33288 γ_1 -Br

- 25 [0050] An approximately 1.9 g sample of the LL-E33288 β -Br complex containing γ -Br from Example 3 was chromatographed on a 25 x 10 cm Sephadex® LH-20 column equilibrated with methanol:water (90:10) at a flow rate of 1.2 ml/minute, collecting 15 ml fractions. The fractions were assayed in the BIA and those active were analysed by TLC as before. Fractions 21-26 containing most of the LL-E33288 β_1 -Br, β_2 -Br and γ_1 -Br, were pooled and concentrated to remove methanol and the resulting aqueous mixture was lyophilized to yield about 435 mg of partially purified complex containing approximately 10% of LL-E33288 β_1 -Br, 1% of LL-E33288 β_2 -Br and 4% of LL-E33288 γ_1 -Br.
- 30 [0051] The above partially purified LL-E33288 β -Br complex containing γ -Br was divided evenly and chromatographed on two 1.5 x 100 cm silica gel columns (Kiesel Gel 60, 40-63 μ m, EM Products for chromatography) packed and equilibrated with ethyl acetate:methanol (98:2) at a flow rate of 1 ml/minute, collecting 12 ml fractions. The fractions were assayed and analysed by TLC as before and those containing primarily LL-E33288 β_1 -Br were pooled, concentrated and precipitated from hexane to yield about 26 mg of 80% pure LL-E33288 β_1 -Br. Those fractions containing LL-E33288 γ_1 -Br (chromatographing just after LL-E33288 β_1 -Br) were pooled and worked up to yield about 4.5 mg of 30% pure LL-E33288 γ_1 -Br. A few fractions containing LL-E33288 β_2 -Br (chromatographing just before LL-E33288 β_1 -Br), were pooled and worked up to yield a trace amount of LL-E33288 β_2 -Br.
- 35
- 40

Example 5Final Purification of LL-E33288 β_1 -Br

- 45 [0052] The approximately 26 mg of 80% pure LL-E33288 β_1 -Br from Example 4 was combined with other LL-E33288 β_1 -Br samples of similar purity derived from other fermentations conducted under identical conditions. A total of about 38 mg of this combined β_1 -Br was further purified by reverse phase preparative TLC using Whatman PLKC₁₈F, 100 m precoated TLC plates, developed with methanol:0.1M ammonium acetate buffer at pH 4.0 (90:10). The band containing LL-E33288 β_1 -Br, chromatographing at R_f=0.66 and visualized by quenching effect under short wavelength UV lamp (254 nm), was-excised and the antibiotic was washed off the adsorbant with 10% isopropyl alcohol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate. The solution was concentrated and the residue was dissolved in ethyl acetate and washed with a small amount of water. The organic solution containing LL-E33288 β_1 -Br was worked up as before to yield about 24.5 mg of 90% pure LL-E33288 β_1 -Br. This sample was further purified by preparative TLC on silica gel (Silica Gel GF precoated plates, 1000 m, Analtech) developed with 3% isopropyl alcohol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate. The major quenching band under short wavelength UV lamp (254 nm), chromatographing at R_f=0.7, was excised and the antibiotic was washed off the adsorbant with dichloromethane:methanol (80:20). The organic solution containing LL-E33288 β_1 -Br was worked up as before to yield about 18.8 mg of substantially pure LL-E33288 β_1 -Br.
- 50
- 55

Example 6Final Purification of LL-E33288 β_1 -Br

- 5 [0053] The approximately 4.5 mg of 30% pure LL-E33288 γ_1 -Br from Example 4 was combined with other LL-E33288 γ_1 -Br samples of similar purity derived from other fermentations conducted under identical conditions. A total of 18 mg of this combined sample was further purified by preparative TLC on silica gel (Silica Gel GF precoated tapered plates, Analtech) developed with 2% isopropyl alcohol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate. The major quenching band under short wavelength UV lamp (254 nm), chromatographing at $R_f=0.5$, was excised and worked up as before to yield about 4.3 mg of substantially pure LL-E33288 γ_1 -Br.
- 10 [0054] A preferred fermentation medium for production of LL-E33288 Bromo-complex is as follows:

Ingredient	Percent
Sucrose	2.0
Ferrous Sulfate Heptahydrate	0.01
Magnesium Sulfate Heptahydrate	0.02
Calcium Carbonate	0.5
Peptone	0.2
Molasses	0.5
Sodium Bromide	0.05
Water qs to	100

- 25 [0055] However, the addition of iodine as potassium iodide, to the fermentation medium provided substantial improvements by:

- 1) markedly enhancing vegetative growth in the fermentation;
- 2) increasing zones of inhibition in bioassays versus Escherichia coli #300 and Bacillus subtilis #308;
- 30 3) providing substantial activity at the R_f of LL-E33288 β_1 -I and γ_1 -I on the bioautography of TLC plates; and
- 4) enhancement of other components as detected by TLC.

- 35 [0056] The following two media are preferred for the production of LL-E33288 Iodo-complex:

Ingredient	Percent	
	Media A	Media B
Sucrose	2.0	2.0
Ferrous Sulfate Heptahydrate	0.01	0.01
Magnesium Sulfate Heptahydrate	0.02	0.02
Calcium Carbonate*	0.5	0.25
Peptone**	0.2	0.2
Molasses	0.5	0.5
Potassium iodide	0.05	0.01
Water qs to	100	100

* Mississippi lime.

** Best results were obtained with MARCOR® bacteriological peptone, but other peptones usable and also polypeptides from meat and casein hydrolyzates.

Example 7

- 55 [0057] A mycelial-spore suspension was prepared by scraping the surface of a slant of culture NRRL-15839 to which 5 ml of sterile distilled water had been added. This suspension was then used to inoculate 100 ml of sterile seed medium of the following formula:

5

Yeast Extract		0.5%
Beef Extract		0.3%
Tryptose		0.5%
Starch		2.4%
Dextrose		0.5%
Calcium Carbonate		0.4%
Water	qs	to 100.0%

10

in a 500 ml flask. This seed flask was incubated at 28°C on a rotary shaker at 200 rpm for 3-4 days, producing Stage I inoculum.

[0058] The Stage I inoculum was used to inoculate a Stage II inoculum of the same sterile medium, which was incubated under the same conditions for 2 days.

15

[0059] The Stage II inoculum was then used to inoculate 100 ml of sterile fermentation medium of the formula:

20

Sucrose		2.0%
Ferrous Sulfate Heptahydrate		0.01%
Magnesium Sulfate Heptahydrate		0.02%
Calcium Carbonate		0.5%
Peptone (MARCOR®)		0.2%
Molasses		0.5%
Potassium Iodide		0.05%
Water	qs	to 100.0%

25

[0060] This medium was incubated at 28°C on a shaker at 200 rpm for 5 days at which time the mash was harvested.

[0061] A concentration of 4 to 20 µg/ml of potassium iodide appears to be optimal, but concentrations of 2 mg/ml do not appear to depress yields.

30

[0062] NRRL-15839 can be induced to produce LL-E33288 β_1 -I when potassium iodide is present in the medium, but only at very low levels (0.2-0.3 µg/ml) as against 1.5-3.5 µg/ml for the better producing NRRL-15975.

[0063] Yields of β_1 -I and γ_1 -I in an iodine medium are 2 to 8 times greater than yields of corresponding brominated compounds β_1 -Br and γ_1 -Br in a bromine medium using NRRL-15975.

35

Example 8

Separation of LL-E33288 α_1 -I, α_2 -I, and α_3 -I from LL-E33288 β_1 -I, β_2 -I, γ_1 -I and δ_1 -I

40

[0064] Approximately 41.3 g of crude LL-E33288 complex derived from the processing 7500 liters of a fermentation using NRRL-15975 and medium containing inorganic iodide was divided evenly into two portions and chromatographed on two separate 2.5 x 110 cm silica gel column (Silica Woelm, 32-63 um) packed and equilibrated with ethyl acetate. The columns were first eluted with ethyl acetate at a flow rate of 4 ml/minute for 4 hours, collecting 20 ml fractions. The eluent was changed to a concave gradient from ethyl acetate saturated with 0.1 M aqueous potassium dihydrogen phosphate to 10% isopropyl alcohol in ethyl acetate saturated with 0.1 M aqueous potassium dihydrogen phosphate over 24 hours. The columns were finally eluted with 10% isopropyl alcohol in ethyl acetate saturated with 0.1 M aqueous potassium dihydrogen phosphate over night. The fractions were assayed in the BIA and those active were analysed by TLC as described in Example 3.

[0065] Fractions (86-107) containing LL-E33288 α_3 -I from the two columns were pooled and worked up as before to yield about 2.1 g of crude LL-E33288 α_3 -I.

50

[0066] Fractions (182-253) containing LL-E33288 α_1 -I and α_2 -I from the two columns were pooled and worked up to yield about 4.2 g of a crude mixture of LL-E33288 α_1 -I and α_2 -I.

[0067] Fractions (254-272) containing LL-E33288 β_2 -I and β_1 -I from the two columns were pooled and worked up to yield about 1.2 g of a crude mixture of LL-E33288 β_2 -I and β_1 -I.

55

[0068] Fractions (273-302) containing LL-E33288 γ_1 -I from the two columns were pooled and worked up to yield about 1.9 g of 30% pure LL-E33288 γ_1 -I.

[0069] Fractions (303-340) containing LL-E33288 δ_1 -I from the two columns were pooled and worked up to yield about 1.3 g of partially purified LL-E33288 δ_1 -I.

Example 9Purification of LL-E33288 γ_1 -I

- 5 [0070] Approximately 900 mg of the 30% pure LL-E33288 γ_1 -I from Example 8 was chromatographed on a 2.5 x 120 cm sephadex LH-20 column equilibrated with ethyl acetate:dichloromethane:ethanol (2:2:1) at a flow rate of 1 ml/minute, collecting 12 ml fractions. The fractions were assayed and analysed by TLC as before and those containing LL-E33288 γ_1 -I (fractions 24-33) were pooled and worked up to yield 428 mg of 64% pure LL-E33288 γ_1 -I.
- 10 [0071] A 22 mg sample of the above was chromatographed on a 0.8 x 24 cm Seprylate C₁₈ (35-60 um, Analytichem) column equilibrated with acetonitrile:0.2 M aqueous ammonium acetate (55.45) at a flow rate of 2 ml/minute, collecting 12 ml fractions. The fractions were assayed and analysed by TLC as before and those containing pure LL-E33288 γ_1 -I were pooled and worked up to yield 7.7 mg of pure LL-E33288 γ_1 -I.

Example 10Purification of LL-E33288 β_1 -I and β_2 -I

- 20 [0072] Approximately 600 mg of the crude mixture of LL-E33288 β_2 -I and β_1 -I from Example 8 was chromatographed on a 2.5 x 120 cm Sephadex LH-20 column equilibrated with ethyl acetate:dichloromethane:ethanol (2:2:1) at a flow rate of 1 ml/minute, collecting 12 ml fractions. The fractions were assayed and analysed by TLC as before and those containing LL-E33288 β_2 -I and LL-E33288 β_1 -I (fractions 23-31) were pooled and worked up to yield 81 mg of a partially purified mixture of LL-E33288 β_2 -I and β_1 -I.
- [0073] The sample above was chromatographed on a 1.5 x 90 cm Sephadex LH-20 column equilibrated with hexane: dichloromethane:ethanol (3:1:1) at a flow rate of 0.8 ml/minute, collecting 12 ml fractions. The fractions were assayed and analysed by TLC as before and those containing LL-E33288 β_2 -I (fractions 17-30) and LL-E33288 β_1 -I (fractions 31-38) were pooled separately and worked up to yield 31 mg of partially purified LL-E33288 β_2 -I and 20 mg of 80% pure LL-E33288 β_1 -I.

30 **Claims**

1. A compound LL-E33288 α_1 -Br, having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:
- 35 a) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.67;
 b) 3 % isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.80;
 and
 c) ethyl acetate:methanol (95:5), R_f=0.79,
- 40 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 α_1 -Br by a series of column chromatography and assaying and analyzing the compound LL-E33288 α_1 -Br by thin layer chromatography.
- 45 2. A compound LL-E33288 α_2 -Br, having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:
- 50 a) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.61;
 b) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.75;
 and
 c) ethyl acetate:methanol (95:5), R_f=0.73;

55 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine

and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calichensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 α_2 -Br by a series of column chromatography and assaying and analyzing the compound LL-E33288 α_2 -Br by thin layer chromatography.

- 5 3. A compound LL-E33288 α_3 -Br having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

- 10 a) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.55;
 b) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.69;
 15 and
 c) ethyl acetate:methanol (95:5), R_f=0.61;

20 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calichensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 α_3 -Br by a series of column chromatography and assaying and analyzing the compound LL-E33288 α_3 -Br by thin layer chromatography.

- 25 4. A compound LL-E33288 α_4 -Br, having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

- 30 a) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.49;
 b) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.64;
 35 and
 c) ethyl acetate:methanol (95:5), R_f=0.54,

40 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calichensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24-32°C for a period of approximately 90-200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and

45 purifying the extracted mixture by selective precipitation from lower hydrocarbons,
 separating LL-E33288 α_4 -Br by a series of column chromatography and
 assaying and analyzing the compound LL-E33288 α_4 -Br by thin layer chromatography.

- 45 5. A compound LL-E33288 β_1 -Br,

- 50 a) having an approximate elemental analysis: C 48.6; H 5.6; N 2.9; S 9.1 and Br 5.5;
 b) having a melting point: 146-150°C (dec.);
 c) having a specific rotation: [α]_D²⁶ = -49±10° (0.1%, ethanol);
 d) having ultraviolet absorption spectra as shown in Figure I of the drawings;
 55 e) having an infrared absorption spectrum as shown in Figure II of the drawings;
 f) having a proton magnetic resonance spectrum as shown in Figure III of the drawings;

EP 0 182 152 B1

g) having a carbon-13 magnetic resonance spectrum as shown in Figure IV of the drawings with significant peaks at:

5	17.60(q); 22.4(q); 36.9(t); 52.7(q); 57.8(d); 66.9(d); 70.2(d); 76.1(d); 97.4(d); 115.1(s); 130.2(s); 149.5(s);	17.64(q); 22.8(q); 39.2(t/d); 54.6(d); 61.0(q/d); 68.4(d); 71.1(d); 81.0(d); 99.7(d); 123.4(d); 130.8(s); 191.7(s);	18.9(q); 23.5(q); 47.8(d); 56.3(q); 61.7(d); 69.1(d); 71.9(d); 83.3(s); 100.8(s); 124.4(d); 144.6(s); 192.4(s);	19.7(q); 34.3(t); 51.7(q); 57.2(q); 62.4(t); 69.7(d); 72.1(s); 88.2(s); 102.5(d); 126.5(d); 149.3(s); and
---	--	--	--	--

h) having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

- 20 i) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.24$;
- ii) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.35$;
- 25 iii) ethyl acetate:methanol (95:5), $R_f=0.36$.
- i) having a molecular weight: 1333/1335, respectively for $^{79}\text{Br}/^{81}\text{Br}$; and
- j) having a molecular formula: $\text{C}_{54}\text{H}_{84}\text{N}_3\text{O}_{22}\text{S}_4\text{Br}$.

30 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 β_1 -Br by a series of column chromatography and assaying and analyzing the compound LL-E33288 β_1 -Br by thin layer chromatography.

- 40 6. A compound LL-E33288 β_2 -Br, having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:
- a) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.32$;
- 45 b) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.41$;
and
- c) ethyl acetate:methanol (95:5), $R_f=0.45$,

50 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24-32°C for a period of approximately 90-200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and

- 55 purifying the extracted mixture by selective precipitation from lower hydrocarbons,
separating LL-E33288 β_2 -Br by a series of column chromatography and
assaying and analyzing the compound LL-E33288 β_2 -Br by thin layer chromatography.

EP 0 182 152 B1

7. A compound LL-E33288 γ_1 -Br

- a) having ultraviolet absorption spectra as shown in Figure V of the drawings;
 - 5 b) having an infrared absorption spectrum as shown in Figure VI of the drawings;
 - c) having a proton magnetic resonance spectrum as shown in Figure VII of the drawings; and
 - d) having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:
- 10 i) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.18;
- 15 ii) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.28;
- 15 iii) ethyl acetate:methanol (95:5), R_f=0.27.

- e) having a carbon-13 magnetic resonance spectrum as shown in Figure VIII of the drawings with significant peaks at:

14.4	17.6	17.9	19.0
19.7	-	22.8	-
-	34.0	37.5	39.5
42.1	-	51.6	52.7
54.1	56.3	57.3	-
59.3	61.1	61.8	61.9
67.2	68.18	68.23	69.7
70.1	70.8	71.1	71.7
71.8	76.1	-	81.0
82.9	88.4	-	97.8
100.0	100.2	101.3	103.0
115.3	123.0	124.9	126.9
130.4	131.1	131.8	138.0
144.7	-	149.5	149.6
155.6	192.5	192.9	

- f) having a molecular formula: C₅₅H₇₄N₃O₂₁S₄Br; and

- 40 g) having a molecular weight: 1319/1321, respectively for ⁷⁹Br/⁸¹Br,

producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calichensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 γ_1 -Br by a series of column chromatography and assaying and analyzing the compound LL-E33288 γ_1 -Br by thin layer chromatography.

50 8. A compound LL-E33288 α_1 -I

- a) having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

- 55 i) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.67;

- ii) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.80; and

iii) ethyl acetate:methanol (95:5), $R_f=0.80$; and

b) having a molecular weight:1145, producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts, which medium has been inoculated with a viable culture of the microorganism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24-32°C for a period of approximately 90-200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and

10 purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 α_1 -I by a series of column chromatography and assaying and analyzing the compound LL-E33288 α_1 -I by thin layer chromatography.

9. A compound LL-E33288 α_2 -I

15 a) having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

i) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.61$;

20 ii) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.75$; and

iii) ethyl acetate:methanol (95:5), $R_f=0.73$;

25 b) containing only the following elements: C, H, N, O, S and I;

c) having a molecular weight:1131; and

d) having a proton magnetic resonance spectrum as shown in Figure IX of the drawings,

30 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 α_2 -I by a series of column chromatography and assaying and analyzing the compound LL-E33288 α_2 -I by thin layer chromatography.

10. A compound IL-E33288 α_3 -I

40 a) having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

i) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.55$;

45 ii) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.69$; and

iii) ethyl acetate:methanol (95:5), $R_f=0.61$;

50 b) having a molecular weight:1066; and

c) having a proton magnetic resonance spectrum as shown in Figure x of the drawings,

55 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted

EP 0 182 152 B1

mixtur by selective precipitation from lower hydrocarbons, separating LL-E33288 α_3 -I by a series of column chromatography and assaying and analyzing the compound LL-E33288 α_3 -I by thin layer chromatography.

11. A compound LL-E33288 β_1 -I

5

a) having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

10

i) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.24$;

15

ii) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.35$; and

20

iii) ethyl acetate:methanol (95:5), $R_f=0.36$;

25

b) having an ultraviolet absorption spectra as shown in Figure XI of the drawings;

30

c) having an infrared absorption spectrum as shown in Figure XII of the drawings;

35

d) having a proton magnetic resonance spectrum as shown in Figure XIII of the drawings;

40

e) having a carbon 13 magnetic resonance spectrum as shown in Figure XIV of the drawings with significant peaks at

-	17.5	17.6	18.9
-	22.4	22.8	23.4
25.4	34.3	36.9	39.2
-	47.9	51.6	52.8
54.8	56.3	57.2	57.9
60.9		61.6	62.2
67.0	68.4	68.4	69.1
69.6	70.4	71.1	71.8
72.2	76.2	-	80.8
83.3	88.1	93.6	97.4
99.6	99.6	-	102.6
112.4	123.4	124.4	126.4
-	-	133.4	-
-	192.3	192.6	

f) having a molecular formula: $C_{54}H_{84}N_3O_{22}S_4I$; and

g) having a molecular weight: 1381, producible by

45

aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 β_1 -I by a series of column chromatography and assaying and analyzing the compound LL-E33288 β_1 -I by thin layer chromatography.

50

55

12. A compound LL-E33288 β_2 -I having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

a) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, $R_f=0.32$.

b) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f=0.41; and

c) ethyl acetate:methanol (95:5), R_f=0.45,

5

producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24-32°C for a period of approximately 90-200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and

10

purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288β₂-I by a series of column chromatography and assaying and analyzing the compound LL-E33288β₂-I by thin layer chromatography.

15

13. A compound LL-E33288Y1-I

a) having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

20

- i) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f = 0.18;
- ii) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f = 0.28; and
- iii) ethyl acetate: methanol (95:5), R_f = 0.27;

25

b) containing only the following elements: C, H, N, O, S and I;

c) having an approximate elemental analysis: C 48.8; H 5.4; N 2.8; S 9.0; and I 9.2;

d) having a molecular weight: 1367;

e) having a molecular formula: C₅₃H₈₂N₃O₂₂S₄I;

f) having an ultraviolet absorption spectra as shown in Figure XV of the drawings;

30

g) having an infrared absorption spectrum as shown in Figure XVI of the drawings;

h) having a proton magnetic resonance spectrum as shown in Figure XVII of the drawings; and

i) having a carbon 13 magnetic resonance spectrum as shown in Figure XVIII of the drawings, significant peaks as listed below:

35

14.5(q)	17.6(q)	17.6(q)	18.9(q)
-	-	22.8(q)	-
25.4(q)	34.1(t)	37.0(t)	39.1(t)
42.3(t/s)	-	51.5(d)	52.8(q)
54.8(t)	56.3(q)	57.2(q)	-
60.4(d)	60.9(q)	61.3(t)	61.7(q)
67.0(d)	68.4(d)	68.5(d)	69.2(d)
69.7(d)	70.5(d)	71.1(d)	71.8(d)
72.1(s)	75.7(d)	75.8(d)	80.9(d)
82.8(s)	88.1(s)	93.5(s)	97.3(d)
99.6(d)	99.7(d)	100.8(s)	102.6(d)
-	123.4(d)	124.4(d)	126.2(d)
130.2(s)	131.0(s)	133.4(s)	139.1(s)
143.0(s)	145.1	150.6(s)	151.5(s)
154.5	192.0(s)	192.5(s),	

40

45

50

55

producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted

mixtur by selective pr cipitation from low r hydrocarbons, separating LL-E33288 γ_1 -I by a series of column chromatography and assaying and analyzing the compound LL-E33288 γ_1 -I by thin layer chromatography.

14. A compound LL-E33288 δ_1 -I having the following R_f values in the indicated solvent systems on TLC on silica gel sheets:

- a) ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f = 0.11; and
- b) 3% isopropanol in ethyl acetate saturated with 0.1M aqueous potassium dihydrogen phosphate, R_f = 0.19,

10 producible by aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24 to 32°C for a period of approximately 90 to 200 hours, harvesting the mash and extracting the antibiotics from the fermentation broth with an organic solvent and purifying the extracted mixture by selective precipitation from lower hydrocarbons, separating LL-E33288 δ_1 -I by a series of column chromatography and assaying and analyzing the compound LL-E33288 δ_1 -I by thin layer chromatography.

- 15 15. Use of a compound selected from the group consisting of LL-E33288 α_1 -Br; LL-E33288 α_1 -I; LL-E33288 α_2 -Br; LL-E33288 α_2 -I; LL-E33288 α_3 -Br; LL-E33288 α_3 -I; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_1 -I; LL-E33288 β_2 -Br; LL-E33288 β_2 -I; LL-E33288 γ_1 -Br; LL-E33288 γ_1 -I; and LL-E33288 δ_1 -I for the manufacture of medicaments for treating bacterial infections in warmblooded animals.

- 20 16. Use of a compound selected from the group consisting of LL-E33288 α_1 -Br; LL-E33288 α_1 -I; LL-E33288 α_2 -Br; LL-E33288 α_2 -I; LL-E33288 α_3 -Br; LL-E33288 α_3 -I; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_1 -I; LL-E33288 β_2 -Br; LL-E33288 β_2 -I; LL-E33288 γ_1 -Br; LL-E33288 γ_1 -I; and LL-E33288 δ_1 -I for the manufacture of medicaments for inhibiting the growth of tumors in a mammal.

- 25 17. Use of a compound selected from the group consisting of LL-E33288 α_1 -Br; LL-E33288 α_1 -I; LL-E33288 α_2 -Br; LL-E33288 α_2 -I; LL-E33288 α_3 -Br; LL-E33288 α_3 -I; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_1 -I; LL-E33288 β_2 -Br; LL-E33288 β_2 -I; LL-E33288 γ_1 -Br; LL-E33288 γ_1 -I; and LL-E33288 δ_1 -I for the manufacture of medicaments for regressing leukemia in a mammal.

- 30 18. A process for producing antibiotics LL-E33288 α_1 -Br; LL-E33288 α_2 -Br; LL-E33288 α_3 -Br; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_2 -Br and LL-E33288 γ_1 -Br which comprises aerobically fermenting the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975 in a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts, until substantial antibiotic activity is imparted to said medium and then recovering the antibiotics therefrom.

- 35 19. A process for producing antibiotics LL-E33288 α_1 -Br; LL-E33288 α_2 -Br; LL-E33288 α_3 -Br; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_2 -Br; and LL-E33288 γ_1 -Br which comprises aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, bromine and inorganic salts; which medium has been inoculated with a viable culture of the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24-32°C for a period of approximately 90-200 hours, harvesting the mash and extracting the antibiotics.

- 40 20. A process for producing antibiotics LL-E33288 α_1 -I; LL-E33288 α_2 -I; LL-E33288 α_3 -I; LL-E33288 β_1 -I; LL-E33288 β_2 -I; LL-E33288 γ_1 -I; and LL-E33288 δ_1 -I which comprises aerobically fermenting the organism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975 in a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts, until substantial antibiotic activity is imparted to said medium and then recovering the antibiotics therefrom.

- 45 21. A process for producing antibiotics LL-E33288 α_1 -I; LL-E33288 α_2 -I; LL-E33288 α_3 -I; LL-E33288 β_1 -I; LL-E33288 β_2 -I; LL-E33288 γ_1 -I; and LL-E33288 δ_1 -I which comprises aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen, iodine and inorganic salts, which medium has been inoculated with a viable culture of the microorganism Micromonospora echinospora ssp. calicensis NRRL 15839 or mutants thereof including NRRL 15975, maintaining said fermentation culture at a temperature of about 24-32°C for a period of approximately 90-200 hours, harvesting the mash and extracting the antibiotics.

22. A cultur containing the microorganism Micromonospora chinospora ssp. calichensis, NRRL 15839, said culture being capable of producing the LL-E33288 complex in recoverable quantity upon aerobic fermentation in an aqueous medium containing assimilabl sources of carbon nitrogen, inorganic salts, and either iodine or bromine or both.
- 5 23. A culture containing the microorganism Micromonospora echinospora ssp. calichensis NRRL 15975, said culture being capable of producing the LL-E33288 complex in recoverable quantity upon aerobic fermentation in an aqueous medium containing assimilable sources of carbon, nitrogen, inorganic salts, and either iodine or bromine or both.

10

Patentansprüche

1. Verbindung LL-E33288 α_1 -Br mit den folgenden R_f-Werten im angegebenen Lösungsmittelsystem bei Dünnschichtchromatographie auf Silikagel-Platten:

15

- a) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,67;
b) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,80; und
c) Ethylacetat:Methanol (95:5), R_f=0,79,

20

herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calichensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 α_1 -Br durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 α_1 -Br mittels Dünnschichtchromatographie.

25

2. Verbindung LL-E33288 α_2 -Br mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- a) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,61;
b) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,75; und
c) Ethylacetat:Methanol (95:5), R_f=0,73;

30

herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calichensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernen des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 α_2 -Br durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 α_2 -Br mittels Dünnschichtchromatographie.

35

3. Verbindung LL-E33288 α_3 -Br mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- a) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,55;
b) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,69; und
c) Ethylacetat:Methanol (95:5), R_f=0,61;

40

herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calichensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernen des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 α_3 -Br durch eine Reihe von Säulenchromatographien

EP 0 182 152 B1

und Untersuchen und Analysieren der Verbindung LL-E33288 α_3 -Br mittels Dünnschichtchromatographie.

4. Verbindung LL-E33288 α_4 -Br mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten;

- 5
 a) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,49;
 b) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,64; und
 c) Ethylacetat:Methanol (95:5), R_f=0,54;

10 herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitspanne von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe
 15 mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 α_4 -Br durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 α_4 -Br mittels Dünnschichtchromatographie.

5. Verbindung LL-E33288 β_1 -Br

- 20
 a) mit einer annähernden Elementaranalyse:
 C 48,6; H 5,6; N 2,9; S 9,1 und Br 5,5;
 b) mit einem Schmelzpunkt: 146-150°C (Zers.);
 25 c) mit einer spezifischen Drehung: [α]_D²⁶=-49±10° (0,1%, Ethanol);
 d) mit Ultraviolet-Absorptionsspektren wie in Fig. I der Zeichnungen gezeigt;
 e) mit einem Infrarotspektrum, wie in Fig. II der Zeichnungen gezeigt;
 f) mit einem Protonen-Magnetresonanzspektrum, wie in Fig. III der Zeichnungen gezeigt;
 g) mit einem Kohlenstoff-13-Magnetresonanzspektrum, wie in Fig. IV der Zeichnungen gezeigt, mit signifikanten Peaks bei:

30	17,60(q); 22,4(q); 36,9(t); 52,7(q); 57,8(d); 66,9(d); 70,2(d); 76,1(d); 97,4(d); 115,1(s); 130,2(s); 149,5(s);	17,64(q); 22,8(q); 39,2(t/d); 54,6(d); 61,0(q/d); 68,4(d); 71,1(d); 81,0(d); 99,7(d); 123,4(d); 130,8(s); 191,7(s);	18,9(q); 23,5(q); 47,8(d); 56,3(q); 61,7(d); 69,1(d); 71,9(d); 83,3(s); 100,8(s); 124,4(d); 144,6(s); 192,4(s);	19,7(q); 34,3(t); 51,7(q); 57,2(q); 62,4(t); 69,7(d); 72,1(s); 88,2(s); 102,5(d); 126,5(d); 149,3(s); und
----	--	--	--	--

- 45 h) mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- 50 i) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,24;
 ii) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,35; und
 iii) Ethylacetat:Methanol (95:5), R_f=0,36;
 i) mit einem Molekulargewicht: 1333/1335, für ⁷⁹Br bzw. ⁸¹Br; und
 j) mit einer Molekülformel: C₅₄H₉₄N₃O₂₂S₄Br,

- 55 herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975,

EP 0 182 152 B1

b) impft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 β_1 -Br durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 β_1 -Br mittels Dünnschichtchromatographie.

- 5 6. Verbindung LL-E33288 β_2 mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- 10 a) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,32;
 b) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,41; und
 c) Ethylacetat:Methanol (95:5), R_f=0,45;

15 herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 β_2 -Br durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 β_2 -Br mittels Dünnschichtchromatographie.

- 20 7. Verbindung LL-E33288 γ_1 -Br

- 25 a) mit Ultraviolet-Absorptionsspektren wie in Fig. V der Zeichnungen gezeigt;
 b) mit einem Infrarot-Absorptionsspektrum, wie in Fig. VI der Zeichnungen gezeigt;
 c) mit einem Protonen-Magnetresonanzspektrum, wie in Fig. VII der Zeichnungen gezeigt; und
 d) mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- 30 i) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,18;
 ii) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,28; und
 iii) Ethylacetat:Methanol (95:5), R_f=0,27;

- 35 e) mit einem Kohlenstoff-13-Magnetresonanzspektrum, wie in Fig. VIII der Zeichnungen gezeigt, mit signifikanten Peaks bei:

14,4	17,6	17,9	19,0
19,7	-	22,8	-
-	34,0	37,6	39,5
42,1	-	51,6	52,7
54,1	56,3	57,3	-
59,3	61,1	61,8	61,9
67,2	68,18	68,23	69,7
70,1	70,8	71,1	71,7
71,8	76,1	-	81,0
82,9	88,4	-	97,8
100,0	100,2	101,3	103,0
115,3	123,0	124,9	126,9
130,4	131,1	131,8	138,0
144,7	-	149,5	149,6
155,6	192,5	192,9	

- 40 f) mit einer Molekülformel: C₅₅H₇₄N₃O₂₁S₄Br;
 und
 g) mit einem Molekulargewicht 1319/1321 für ⁷⁹Br bzw. ⁸¹Br, herstellbar durch aerobe Fermentation eines

flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitspanne von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 γ_1 -Br durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 γ_1 -Br mittels Dünnschichtchromatographie.

5 10 8. Verbindung LL-E33288 α_1 -

a) mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- 15 i) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,67;
 ii) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,80; und
 iii) Ethylacetat:Methanol (95:5), R_f=0,80; und b) mit einem Molekulargewicht: 1145, herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Mikroorganismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitspanne von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 α_1 -I durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 α_1 -I mittels Dünnschichtchromatographie.

20 25 9. Verbindung LL-E33288 α_2 -

30 a) mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- 35 i) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,61;
 ii) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,75; und
 iii) Ethylacetat:Methanol (95:5), R_f=0,73;
- b) welches nur die folgenden Elemente enthält: C, H, N, O, S und I;
 c) mit einem Molekulargewicht: 1131; und
 d) mit einem Protonen-Magnetresonanzspektrum, wie in Fig. IX der Zeichnungen gezeigt,

40 45 herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitspanne von etwa 90 bis 200 Stunden, Erten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 α_2 -I durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 α_2 -I mittels Dünnschichtchromatographie.

50 10. Verbindung LL-E33288 α_3 -

a) mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- 55 i) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,55;
 ii) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,69; und
 iii) Ethylacetat:Methanol (95:5), R_f=0,61;

EP 0 182 152 B1

- b) mit einem Molekulargewicht: 1066; und
 c) mit einem Protonen-Magnetresonanzspektrum, wie in Fig. X der Zeichnung n gezeigt,

herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 α_3 -I durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 α_3 -I mittels Dünnschichtchromatographie.

11. Verbindung LL-E33288 β_1 -I

- a) mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- i) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,24;
 ii) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,35; und
 iii) Ethylacetat:Methanol (95:5), R_f=0,36;

- b) mit einem Ultraviolet-Absorptionsspektrum wie in Fig. XI der Zeichnungen gezeigt;
 c) mit einem Infrarot-Absorptionsspektrum, wie in Fig. XII der Zeichnungen gezeigt;
 d) mit einem Protonen-Magnetresonanzspektrum, wie in Fig. XIII der Zeichnungen gezeigt;
 e) mit einem Kohlenstoff-13-Magnetresonanzspektrum, wie in Fig. XIV der Zeichnungen gezeigt, mit signifikanten Peaks bei:

-	17,5	17,6	18,9
-	22,4	22,8	23,4
25,4	34,3	36,9	39,2
-	47,9	51,6	52,8
54,8	56,3	57,2	57,9
60,9		61,6	62,2
67,0	68,4	68,4	69,1
69,6	70,4	71,1	71,8
72,2	76,2	-	80,8
83,3	88,1	93,6	97,4
99,6	99,6	-	102,6
112,4	123,4	124,4	126,4
-	-	133,4	-
-	-	-	-
-	192,3	192,6	

- f) mit einer Molekülformel: C₅₄H₈₄N₃O₂₂S₄I; und
 g) mit einem Molekulargewicht 1381, herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernen des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 β_1 -I durch eine Reihe von Säulenchromatographien und untersuchen und Analysieren der Verbindung LL-E33288 β_1 -I mittels Dünnschichtchromatographie.

12. Verbindung LL-E33288 β_2 -I mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

EP 0 182 152 B1

- a) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, $R_f=0,32$;
- b) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, $R_f=0,41$; und
- c) Ethylacetat:Methanol (95:5), $R_f=0,45$,

5 herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitspanne von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 β_2 -I durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 β_2 -I mittels Dünnschichtchromatographie.

13. Verbindung LL-E33288 γ_1 -I,

- 15 a) mit den folgenden R_f -Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:
- i) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, $R_f=0,18$;
 - ii) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat $R_f=0,28$; und
 - iii) Ethylacetat:Methanol (95:5), $R_f=0,27$;
- b) welches nur die folgenden Elemente enthält: C, H, N, O, S und I;
- c) mit einer annähernden Elementaranalyse: C 48,8; H 5,4; N 2,8; S 9,0; und I 9,2;
- d) mit einem Molekulargewicht: 1367;
- e) mit einer Molekülfomel: $C_{53}H_{82}N_3O_{22}S_4I$;
- f) mit einem Ultraviolet-Absorptionsspektrum wie in Fig. XV der Zeichnungen gezeigt;
- g) mit einem Infrarot-Absorptionsspektrum, wie in Fig. XVI der Zeichnungen gezeigt;
- h) mit einem Protonen-Magnetresonanzspektrum, wie in Fig. XVII der Zeichnungen gezeigt; und
- 30 i) mit einem Kohlenstoff-13-Magnetresonanzspektrum, wie in Fig. XVIII der Zeichnungen gezeigt, mit signifikanten Peaks wie nachfolgend aufgezählt;

	14,5(q)	17,6(q)	17,6(q)	18,9(q)
35	-	-	22,8(q)	-
	25,4(q);	34,1(t)	37,0(t)	39,1(t)
	42,3(t/s)	-	51,5(d)	52,8(q)
	54,8(t)	56,3(q)	57,2(q)	-
40	60,4(d)	60,9(q)	61,3(t)	61,7(q)
	67,0(d)	68,4(d)	68,5(d)	69,2(d)
	69,7(d)	70,5(d)	71,1(d)	71,8(d)
	72,1(s)	75,7(d)	75,8(d)	80,9(d)
	82,8(s)	88,1(s)	93,5(s)	97,3(d)
45	99,6(d)	99,7(d)	100,8(s)	102,6(d)
	-	123,4(d)	124,4(d)	126,2(d)
	130,2(s)	131,0(s)	133,4(s)	139,1(s)
	143,0(s)	145,1	150,6(s)	151,5(s)
50	154,5	192,0(s)	192,5(s),	

herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitspanne von etwa 90 bis 200 Stunden, Ernen des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 γ_1 -I durch eine Reihe von Säulenchromatographien

und Untersuchen und Analysieren der Verbindung LL-E33288 γ_1 -I mittels Dünnschichtchromatographie.

14. Verbindung LL-E33288 δ_1 -I mit den folgenden R_f-Werten in den angegebenen Lösungsmittelsystemen bei Dünnschichtchromatographie auf Silikagel-Platten:

- 5 a) Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,11; und
b) 3% Isopropanol in Ethylacetat, gesättigt mit 0,1M wässrigem Kaliumdihydrogenphosphat, R_f=0,19,

10 herstellbar durch aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält; welches Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24 bis 32°C für eine Zeitdauer von etwa 90 bis 200 Stunden, Ernten des breiigen Gemisches und Extrahieren der Antibiotika aus der Fermentationsbrühe mit einem organischen Lösungsmittel und Reinigen der extrahierten Mischung durch selektives Ausfällen aus niedrigen Kohlenwasserstoffen, Abtrennen von LL-E33288 δ_1 -I durch eine Reihe von Säulenchromatographien und Untersuchen und Analysieren der Verbindung LL-E33288 δ_1 -I mittels Dünnschichtchromatographie.

- 15 15. Verwendung einer Verbindung ausgewählt aus der Gruppe bestehend aus LL-E33288 α_1 -Br; LL-E33288 α_1 -I; LL-E33288 α_2 -Br; LL-E33288 α_2 -I; LL-E33288 α_3 -Br; LL-E33288 α_3 -I; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_1 -I; LL-E33288 β_2 -Br; LL-E33288 β_2 -I; LL-E33288 γ_1 -Br; LL-E33288 γ_1 -I; und LL-E33288 δ_1 -I zur Herstellung von Medikamenten zur Behandlung bakterieller Infektionen bei Warmblütern.

- 20 16. Verwendung einer Verbindung ausgewählt aus der Gruppe bestehend aus LL-E33288 α_1 -Br; LL-E33288 α_1 -I; LL-E33288 α_2 -Br; LL-E33288 α_2 -I; LL-E33288 α_3 -Br; LL-E33288 α_3 -I; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_1 -I; LL-E33288 β_2 -Br; LL-E33288 β_2 -I; LL-E33288 γ_1 -Br; LL-E33288 γ_1 -I; und LL-E33288 δ_1 -I zur Herstellung von Medikamenten zur Hemmung des Wachstums von Tumoren bei einem Säuger.

- 25 17. Verwendung einer Verbindung ausgewählt aus der Gruppe bestehend aus LL-E33288 α_1 -Br; LL-E33288 α_1 -I; LL-E33288 α_2 -Br; LL-E33288 α_2 -I; LL-E33288 α_3 -Br; LL-E33288 α_3 -I; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_1 -I; LL-E33288 β_2 -Br; LL-E33288 β_2 -I; LL-E33288 γ_1 -Br; LL-E33288 γ_1 -I; und LL-E33288 δ_1 -I zur Herstellung von Medikamenten zur Regression von Leukämie bei einem Säuger.

- 30 18. Verfahren zur Herstellung der Antibiotika LL-E33288 α_1 -Br; LL-E33288 α_2 -Br; LL-E33288 α_3 -Br; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_2 -Br und LL-E33288 γ_1 -Br, welches die aerobe Fermentation des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, in einem flüssigen Medium enthaltend assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze, bis dem Medium eine im wesentlichen antibiotische Aktivität verliehen ist, und die nachfolgende Gewinnung der Antibiotika aus diesem umfaßt.

- 35 19. Verfahren zur Herstellung der Antibiotika LL-E33288 α_1 -Br; LL-E33288 α_2 -Br; LL-E33288 α_3 -Br; LL-E33288 α_4 -Br; LL-E33288 β_1 -Br; LL-E33288 β_2 -Br und LL-E33288 γ_1 -Br, welches die aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Brom und anorganische Salze enthält, wobei das Medium mit einer lebensfähigen Kultur des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder Mutanten davon, einschließlich NRRL 15975, beimpft ist, das Halten der Fermentationskultur auf einer Temperatur von etwa 24-32°C für eine Zeitdauer von etwa 90-200 Stunden, Ernten des breiigen Gemisches und Extraktion der Antibiotika umfaßt.

- 40 20. Verfahren zur Herstellung der Antibiotika LL-E33288 α_1 -I; LL-E33288 α_2 -I; LL-E33288 α_3 -I; LL-E33288 β_1 -I; LL-E33288 β_2 -I; LL-E33288 γ_1 -I; und LL-E33288 δ_1 -I, welches die aerobe Fermentation des Organismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder von Mutanten desselben, einschließlich NRRL 15975, in einem flüssigen Medium, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält, bis dem Medium im wesentlichen antibiotische Aktivität verliehen worden ist, und nachfolgende Gewinnung der Antibiotika aus diesem umfaßt.

- 45 21. Verfahren zur Herstellung der Antibiotika LL-E33288 α_1 -I; LL-E33288 α_2 -I; LL-E33288 α_3 -I; LL-E33288 β_1 -I; LL-E33288 β_2 -I; LL-E33288 γ_1 -I; und LL-E33288 δ_1 -I, welches die aerobe Fermentation eines flüssigen Mediums, das assimilierbare Quellen für Kohlenstoff, Stickstoff, Jod und anorganische Salze enthält, wobei das Medium mit einer lebensfähigen Kultur des Mikroorganismus Micromonospora echinospora ssp. calicensis NRRL 15839 oder von

Mutanten desselben, einschließlich NRRL 15975, beimpft ist, Halten der Fermentationskultur auf einer Temperatur von etwa 24-32°C für eine Zeitdauer von etwa 90-200 Stunden, Ernten des breiigen Gemisches und Extraktion der Antibiotika umfaßt.

- 5 22. Kultur, die den Mikroorganismus Micromonospora echinospora ssp. calichensis NRRL 15839 aufweist, wobei die Kultur fähig ist, den LL-E33288-Komplex in gewinnbarer Menge nach aerober Fermentation in einem wässrigen Medium, das assimilierbare Quellen für Kohlenstoff, Stickstoff, anorganische Salze und entweder Jod oder Brom oder beides enthält, zu erzeugen.
- 10 23. Kultur, die den Mikroorganismus Micromonospora echinospora ssp. calichensis NRRL 15975 aufweist, wobei die Kultur fähig ist, den LL-E33288-Komplex in gewinnbarer Menge nach aerober Fermentation in einem wässrigen Medium, das assimilierbare Quellen für Kohlenstoff, Stickstoff, anorganische Salze und entweder Jod oder Brom oder beides enthält, zu erzeugen.

15

Revendications

1. Composé LL-E33288 α_1 -Br, ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

20

- a) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,67$;
- b) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,80$, et
- c) acétate d'éthyle:méthanol (95:5), $R_f = 0,79$, pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calichensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 α_1 -Br par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 α_1 -Br par chromatographie en couche mince.

25

2. Composé LL-E33288 α_2 -Br, ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

30

- a) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,61$;
- b) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,75$, et
- c) acétate d'éthyle:méthanol (95:5), $R_f = 0,73$, pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calichensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 α_2 -Br par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 α_2 -Br par chromatographie en couche mince.

35

3. Composé LL-E33288 α_3 -Br, ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

40

- a) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,55$;
- b) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,69$, et
- c) acétate d'éthyle:méthanol (95:5), $R_f = 0,61$, pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calichensis NRRL 15839

EP 0 182 152 B1

ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 α_3 -Br par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 α_3 -Br par chromatographie en couche mince.

- 4.** Composé LT-E33288 α_4 -Br, ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice ;

a) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,49$;
 b) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,64$, et
 c) acétate d'éthyle:méthanol (95:5), $R_f = 0,54$, pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 α_4 -Br par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 α_4 -Br par chromatographie en couche mince.

- 5.** Composé LL-E33288 β_1 -Br,

a) ayant une analyse élémentaire approximative : C 48,6; H 5,6; N 2,9; S 9,1 et Br 5,5;
 b) ayant un point de fusion : 146-150°C (déc.);
 c) ayant un pouvoir rotatoire spécifique : $[\alpha]_D^{26} = -49 \pm 10^\circ$ (0,1%, éthanol);
 d) ayant un spectre d'absorption dans l'ultraviolet comme le montre la Fig. 1 des dessins;
 e) ayant un spectre d'absorption dans l'infrarouge comme le montre la Fig. 2 des dessins;
 f) ayant un spectre de résonance magnétique nucléaire du proton comme le montre la Fig. 3 des dessins;
 g) ayant un spectre de résonance magnétique nucléaire du carbone 13 comme le montre la Fig. 4 des dessins, avec des pics significatifs à :

17,60(q);	17,64(q);	18,9(q);	19,7(q);
22,4(q);	22,8(q);	23,5(q);	34,3(t);
36,9(t);	39,2(t/d);	47,8(d);	51,7(q);
52,7(q);	54,6(d);	56,3(q);	57,2(q);
57,8(d);	61,0(q/d);	61,7(d);	62,4(t);
66,9(d);	68,4(d);	69,1(d);	69,7(d);
70,2(d);	71,1(d);	71,9(d);	72,1(s);
76,1(d);	81,0(d);	83,3(s);	88,2(s);
97,4(d);	99,7(d);	100,8(s);	102,5(d);
115,1(s);	123,4(d);	124,4(d);	126,5(d);
130,2(s);	130,8(s);	144,6(s);	149,3(s);
149,5(s);	191,7(s);	192,4(s);	et

h) ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- i) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,24$;
 ii) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,35$, et
 iii) acétate d'éthyle:méthanol (95:5), $R_f = 0,36$;

EP 0 182 152 B1

- i) ayant un poids moléculaire : 1333/1335, respectivement pour $^{79}\text{Br}/^{81}\text{Br}$, et
- ii) ayant un formule moléculaire : $\text{C}_{54}\text{H}_{64}\text{N}_3\text{O}_{22}\text{S}_4\text{Br}$.

5 pouvant être produit par fermentation aérobiose d'un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, 10 par séparation du LL-E33288 β_1 -Br par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 β_1 -Br par chromatographie en couche mince.

- 15 6. Composé LL-E33288 β_2 -Br, ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

a) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,32$;
 b) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,41$, et
 c) acétate d'éthyle:méthanol (95:5), $R_f = 0,45$, pouvant être produit par fermentation aérobiose d'un milieu liquide 20 contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange 25 extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 β_2 -Br par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 β_2 -Br par chromatographie en couche mince.

- 30 7. Composé LL-E33288 γ_1 -Br,

a) ayant un spectre d'absorption dans l'ultraviolet comme le montre la Fig. 5 des dessins;
 b) ayant un spectre d'absorption dans l'infrarouge comme le montre la Fig. 6 des dessins;
 c) ayant un spectre de résonance magnétique nucléaire du proton comme le montre la Fig. 7 des dessins; et
 d) ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel 35 de silice :

i) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,18$;
 ii) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,28$, et
 iii) acétate d'éthyle:méthanol (95:5), $R_f = 0,27$;

40 e) ayant un spectre de résonance magnétique nucléaire du carbone 13 comme le montre la Fig. 8 des dessins, avec des pics significatifs à :

45	14,4	17,6	17,9	19,0
	19,7	-	22,8	-
	-	34,0	37,6	39,5
	42,1	-	51,6	52,7
50	54,1	56,3	57,3	-
	59,3	61,1	61,8	61,9
	67,2	68,18	68,23	69,7
	70,1	70,8	71,1	71,7
	71,8	76,1	-	81,0
55	82,9	88,4	-	97,8
	100,0	100,2	101,3	103,0
	115,3	123,0	124,9	126,9

(suit)

130,4	131,1	131,8	138,0
144,7	-	149,5	149,6
155,6	192,5	192,9	

5

- f) ayant une formule moléculaire : $C_{55}H_{74}N_3O_{21}S_4Br$, et
g) ayant un poids moléculaire : 1319/1321, respectivement pour $^{79}Br/^{81}Br$,

10 pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calichensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 γ_1 -Br par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 γ_1 -Br par chromatographie en couche mince.

15 8. Composé LL-E33288 α_1 -I,

20 a) ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- i) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,67$;
- ii) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,80$, et
- iii) acétate d'éthyle:méthanol (95:5), $R_f = 0,80$, et

25 b) ayant un poids moléculaire de 1145,

30 pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calichensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 α_1 -I par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 α_1 -I par chromatographie en couche mince.

35 9. Composé LL-E33288 α_2 -I,

40 a) ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- i) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,61$;
- ii) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,75$, et
- iii) acétate d'éthyle:méthanol (95:5), $R_f = 0,73$,

45 b) ne contenant que les éléments suivants : C, H, N, O, S et I;
c) ayant un poids moléculaire de 1131, et
d) ayant un spectre de résonance magnétique nucléaire

50 du proton comme le montre la Fig. 9 des dessins, pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calichensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une tempé-

5 rature d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 α_2 -I par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 α_2 -I par chromatographie en couche mince.

10 10. Composé LL-E33288 α_3 -I,

15 a) ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- i) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,55$;
- ii) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,69$, et
- iii) acétate d'éthyle:méthanol (95:5), $R_f = 0,61$;

20 b) ayant un poids moléculaire de 1066, et

25 c) ayant un spectre de résonance magnétique nucléaire

du proton comme le montre la Fig. 10 des dessins, pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calichensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 α_3 -I par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 α_3 -I par chromatographie en couche mince.

30 11. Composé LL-E33288 β_1 -I,

35 a) ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- i) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,24$;
- ii) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,35$, et
- iii) acétate d'éthyle:méthanol (95:5), $R_f = 0,36$;

40 b) ayant un spectre d'absorption dans l'ultraviolet comme le montre la Fig. 11 des dessins;

c) ayant un spectre d'absorption dans l'infrarouge comme le montre la Fig. 12 des dessins;

d) ayant un spectre de résonance magnétique nucléaire du proton comme le montre la Fig. 13 des dessins;

e) ayant un spectre de résonance magnétique nucléaire du carbone 13 comme le montre la Fig. 14 des dessins, avec des pics significatifs à :

-	17,5	17,6	18,9
-	22,4	22,8	23,4
25,4	34,3	36,9	39,2
-	47,9	51,6	52,8
54,8	56,3	57,2	57,9
60,9		61,6	62,2
67,0	68,4	68,4	69,1
69,6	70,4	71,1	71,8
72,2	76,2	-	80,8
83,3	88,1	93,6	97,4
99,6	99,6	-	102,6

EP 0 182 152 B1

(suite)

112,4	123,4	124,4	126,4
-	-	133,4	-
-	-	-	-
-	192,3	192,6	-

- 5 f) ayant une formule moléculaire : $C_{54}H_{84}N_3O_{22}S_4I$, et
 10 b) ayant un poids moléculaire de 1381,

pouvant être produit par fermentation aérobiose d'un milieu liquide contenant des sources assimilables de carbon , d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micro-monospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 15 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 β_1 -I par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 β_1 -I par chromatographie en couche mince.

- 20 12. Composé LL-E33288 β_2 -I, ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- 25 a) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,32$;
 b) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,41$, et
 c) acétate d'éthyle:méthanol (95:5), $R_f = 0,45$,

30 pouvant être produit par fermentation aérobiose d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micro-monospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 35 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 β_2 -I par une série de chromatographies sur colonne et par dosage et analys du composé LL-E33288 β_2 -I par chromatographie en couche mince.

13. Composé LL-E33288 γ_1 -I,

- 40 a) ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- 45 i) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,18$;
 ii) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, $R_f = 0,28$, et
 iii) acétate d'éthyle:méthanol (95:5), $R_f = 0,27$,

- 50 b) ne contenant que les éléments suivants : C, H, N, O, S et I;
 c) ayant une analyse élémentaire approximative : C 48,8; H 5,4; N 2,8; S 9,0 et I 9,2;
 d) ayant un poids moléculaire de 1367;
 e) ayant une formule moléculaire : $C_{53}H_{82}N_3O_{22}S_4I$;
 f) ayant un spectre d'absorption dans l'ultraviolet comme le montre la Fig. 15 des dessins;
 g) ayant un spectre d'absorption dans l'infrarouge comme le montre la Fig. 16 des dessins;
 h) ayant un spectre de résonance magnétique nucléaire du proton comme le montre la Fig. 17 des dessins; et
 i) ayant un spectre de résonance magnétique nucléaire du carbone 13 comme le montre la Fig. 18 des dessins, avec des pics significatifs à :

5	14,5(q)	17,6(q)	17,6(q)	18,9(q)
	-	-	22,8(q)	-
10	25,4(q)	34,1(t)	37,0(t)	39,1(t)
	42,3(t/s)	-	51,5(d)	52,8(q)
	54,8(t)	56,3(q)	57,2(q)	-
	60,4(d)	60,9(q)	61,3(t)	61,7(q)
	67,0(d)	68,4(d)	68,5(d)	69,2(d)
15	69,7(d)	70,5(d)	71,1(d)	71,8(d)
	72,1(s)	75,7(d)	75,8(d)	80,9(d)
	82,8(s)	88,1(s)	93,5(s)	97,3(d)
	99,6(d)	99,7(d)	100,8(s)	102,6(d)
	-	123,4(d)	124,4(d)	126,2(d)
20	130,2(s)	131,0(s)	133,4(s)	139,1(s)
	143,0(s)	145,1	150,6(s)	151,5(s)
	154,5	192,0(s)	192,5(s)	

pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micro-monospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 γ_1 -I par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 γ_1 -I par chromatographie en couche mince.

14. Composé LL-E33288 δ_1 -I ayant les valeurs de R_f suivantes dans les systèmes de solvants indiqués dans des TLC sur feuilles de gel de silice :

- a) acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, R_f = 0,11, et
- b) isopropanol à 3% dans de l'acétate d'éthyle saturé avec du dihydrogénophosphate de potassium aqueux 0,1 M, R_f = 0,19,

35 pouvant être produit par fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micro-monospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques du bouillon de fermentation avec un solvant organique et purification du mélange extrait par précipitation sélective dans des hydrocarbures inférieurs, par séparation du LL-E33288 δ_1 -I par une série de chromatographies sur colonne et par dosage et analyse du composé LL-E33288 δ_1 -I par chromatographie en couche mince.

- 40 15. Utilisation d'un composé sélectionné dans le groupe composé de LL-E33288 α_1 -Br; de LL-E33288 α_1 -I; de LL-E33288 α_2 -Br; de LL-E33288 α_2 -I; de LL-E33288 α_3 -Br; de LL-E33288 α_3 -I; de LL-E33288 α_4 -Br; de LL-E33288 β_1 -Br; de LL-E33288 β_1 -I; de LL-E33288 β_2 -Br; de LL-E33288 β_2 -I; de LL-E33288 γ_1 -Br; de LL-E33288 γ_1 -I, et d'LL-E33288 δ_1 -I, pour la fabrication de médicaments destinés au traitement d'infections bactériennes chez les animaux à sang chaud.

- 45 16. Utilisation d'un composé sélectionné dans le groupe composé de LL-E33288 α_1 -Br; de LL-E33288 α_1 -I; de LL-E33288 α_2 -Br; de LL-E33288 α_2 -I; de LL-E33288 α_3 -Br; de LL-E33288 α_3 -I; de LL-E33288 α_4 -Br; de LL-E33288 β_1 -Br; de LL-E33288 β_1 -I; de LL-E33288 β_2 -Br; de LL-E33288 β_2 -I; de LL-E33288 γ_1 -Br; de LL-E33288 γ_1 -I, et de LL-E33288 δ_1 -I, pour la fabrication de médicaments destinés à inhiber la croissance de tumeurs chez un mammifère.

- 50 17. Utilisation d'un composé sélectionné dans le groupe composé de LL-E33288 α_1 -Br; de LL-E33288 α_1 -I; de LL-E33288 α_2 -Br; de LL-E33288 α_2 -I; de LL-E33288 α_3 -Br; de LL-E33288 α_3 -I; de LL-E33288 α_4 -Br; de LL-E33288 β_1 -

Br; de LL-E33288 β_1 -I; d LL-E33288 β_2 -Br; de LL-E33288 β_2 -I; de LL-E33288 γ_1 -Br; de LL-E33288 γ_1 -I, et de LL-E33288 δ_1 -I, pour la fabrication de médicaments destinés à faire régresser la leucémie chez un mammifère.

- 5 18. Procédé de production d'antibiotiques LL-E33288 α_1 -Br, LL-E33288 α_2 -Br, LL-E33288 α_3 -Br, LL-E33288 α_4 -Br, LL-E33288 β_1 -Br, LL-E33288 β_2 -Br et LL-E33288 γ_1 -Br, lequel comprend la fermentation aérobie de l'organisme Micromonospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975 dans un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, jusqu'à ce qu'une activité antibiotique substantielle soit conférée audit milieu, puis la récupération des antibiotiques à partir de celui-ci.
- 10 19. Procédé de production d'antibiotiques LL-E33288 α_1 -Br, LL-E33288 α_2 -Br, LL-E33288 α_3 -Br, LL-E33288 α_4 -Br, LL-E33288 β_1 -Br, LL-E33288 β_2 -Br et LL-E33288 γ_1 -Br, lequel comprend la fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, de brome et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques,
- 15 20. Procédé de production d'antibiotiques LL-E33288 α_1 -I, LL-E33288 α_2 -I, LL-E33288 α_3 -I, LL-E33288 β_1 -I, LL-E33288 β_2 -I, LL-E33288 γ_1 -I et LL-E33288 δ_1 -I, lequel comprend la fermentation aérobie de l'organisme Micromonospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, dans un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, jusqu'à ce qu'une activité antibiotique substantielle soit conférée audit milieu, puis la récupération des antibiotiques à partir de celui-ci.
- 25 21. Procédé de production d'antibiotiques LL-E33288 α_1 -I, LL-E33288 α_2 -I, LL-E33288 α_3 -I, LL-E33288 β_1 -I, LL-E33288 β_2 -I, LL-E33288 γ_1 -I et LL-E33288 δ_1 -I, lequel comprend la fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels inorganiques, ce milieu ayant été inoculé avec une culture viable de l'organisme Micromonospora echinospora spp. calicensis NRRL 15839 ou des mutants de celui-ci, y compris NRRL 15975, par maintien de ladite culture en fermentation à une température d'environ 24 à 32°C durant une période d'environ 90 à 200 heures, par récolte de la pâte, et par extraction des antibiotiques.
- 30 22. Culture contenant le micro-organisme Micromonospora echinospora spp. calicensis, NRRL 15839, ladite culture étant capable de produire le complexe LL-E33288 en quantité récupérable par fermentation aérobie dans un milieu liquide contenant des sources assimilables de carbone, d'azote, de sels inorganiques, et soit d'iode, soit de brome, soit des deux.
- 35 23. Culture contenant le micro-organisme Micromonospora echinospora spp. calicensis, NRRL 15975, ladite culture étant capable de produire le complexe LL-E33288 en quantité récupérable par fermentation aérobie dans un milieu liquide contenant des sources assimilables de carbone, d'azote, de sels inorganiques, et soit d'iode, soit de brome, soit des deux.
- 40

45

50

55




FIGURE I

INFRARED ABSORPTION SPECTRUM OF LL-E 333288 β_1 -Br

EP 0 182 152 B1




FIGURE II
WAVENUMBERS

EP 0 182 152 B1

PROTON MAGNETIC RESONANCE SPECTRUM
OF LL-E 33288 β_1 -Br




FIGURE III

EP 0 182 152 B1

CARBON 13 MAGNETIC RESONANCE SPECTRUM
OF LL-E 33288 β_1 -Br




FIGURE IV

ULTRAVIOLET ABSORPTION SPECTRA OF LL-E33288 γ_4 -Br
20 $\mu\text{g/ml}$ SOLUTION




FIGURE V

EP 0 182 152 B1

INFRARED ABSORPTION SPECTRUM OF LL-E 33288 γ_1 -Br




FIGURE VI

EP 0 182 152 B1

PROTON MAGNETIC RESONANCE SPECTRUM OF
LL-E33288 γ_1 -Br




FIGURE VII

EP 0 182 152 B1

^{13}C NMR OF LL-E 33288 $\gamma_1\text{-Br}$




FIGURE VIII

EP 0 182 152 B1

PMR OF LL-E 33288 α_2 -I




FIGURE IX

EP 0 182 152 B1

PMR OF LL-E 33288 α_3 -I




FIGURE X

EP 0 182 152 B1




FIGURE XI

EP 0 182 152 B1




FIGURE XII

FIGURE XIII

EP.0 182 152 B1

PMR OF LL-E 33288 β_1 -I




FIGURE XIII

EP 0 182 152 B1

^{13}C NMR OF LL-E33288 β_1 -I





FIGURE XIV

EP 0 182 152 B1



EP 0 182 152 B1

IR OF LL-E33288Y₁-I




FIGURE XVI

EP 0 182 152 B1




FIGURE XVII

EP 0 182 152 B1

^{13}C NMR OF LL-E33288 χ_1 -I




FIGURE XVIII

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)